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CHAPTER I
INTRODUCTION TO P130CAS IN FOCAL ADHESIONS AND CELL
MOTILITY
Principles of Cell Motility
Cell motility is a fundamental process in the development and maintenance of
tissues. The coordinated movement of cells during embryogenesis is a key step in the
proper generation of organs, creation of neuronal linkages, and transport of epithelial
and immune cells into wounds (Ridley et al, 2003). Misregulation of cell motility,
however, can lead to a variety of pathologies including vascular disease, chronic in-
flammation, cancer, and mental retardation (Vicente-Manzanares et al, 2005). Cell
motility can be thought of as a process which occurs cyclically in three steps: 1)
establishment of cortical polarity, 2) protrusion of the cell membrane to adhere to
new sites, and 3) retraction at the rear of the cell (Ridley et al, 2003). Disruption of
any one of these process can lead to a defect in cell motility.
Principles of cortical polarization
The polarization of a cell, or the establishment of a leading and trailing edge,
is thought to be regulated by the positioning of the microtubule organizing center
(MTOC) and the nucleus (Vicente-Manzanares et al, 2005), and has recently been
attributed to the position of the Golgi as well (Miller et al, 2009). Though it has long
been observed that the MTOC and Golgi become oriented with the leading edge in
motile cells (Kupfer et al, 1982), the findings of Miller et al (2009) indicate a more
active role for the Golgi in determining cortical polarity.
Another study has illustrated that the nucleus, not the MTOC, is actively repo-
sitioned to the rear of the cell during directed cell movement, presumably in an actin
1
and Cdc42-dependent manner, and that the MTOC remains stationary as the nucleus
positions itself behind it (Gomes et al, 2005).
Interestingly, inhibition of Src-family kinase (SFK) activity with inhibitors PP1
and PP2 prevents MTOC reorientation and cell protrusion (Etienne-Manneville and
Hall, 2001). Furthermore, integrin engagement appears to be necessary for MTOC
reorientation in this context. At the same time points used for analyzing MTOC re-
orientation, tyrosine phosphorylation of focal adhesion (FA) proteins focal adhesion
kinase (FAK), paxillin, and p130Cas were observed (Etienne-Manneville and Hall,
2001). Therefore it seems that cortical cell polarity is a complex process that likely
involves the nucleus, the MTOC, and the Golgi in integrin-, microtubule-, and actin-
dependent ways.
Principles of protrusion
The formation of membrane protrusions towards a stimulus is an essential step
in cell motility. These protrusive areas are rich in actin filaments. The lamellipodia
— membrane protrusions at the cell’s leading edge — are made of branched actin
networks surfing at the front of larger lamellae (Small et al, 2002). Promotion of
lamellipodial protrusion is associated with the small Rho GTPases Rac and Cdc42
(Matozaki et al, 2000). Cdc42 has also been implicated in the formation of filopodia
(Matozaki et al, 2000) — antenna or finger-like protrusions made up of bundled actin
filaments extending beyond the lamellipodium itself (reviewed in Faix and Rottner
(2006)). However, this view may be too simplistic as evidence has been presented that
Cdc42 is not required for filopodial or lamellipodial formation in fibroblasts (Czuchra
et al, 2005). Filopodia are often thought of as the sensory antennae of the cell,
whereby the cell can sense extracellular stimuli and reorient the cell in the direction
of that stimulus (Small et al, 2002).
In addition to these protrusive structures, the cell must form new sites of adhesion
2
from which it can exert contractile forces to propel itself forward. These forces are
generated through adhesion sites at the ventral surface of the cell that connect the
cell to the substratum via integrins (heterodimeric receptors responding to ECM
ligands). The molecular makeup of these ECM/cell contacts will be further discussed
in the section entitled “ECM/cell contacts: sites of ECM/actin linkage and pro-motile
signaling”. These sites, often referred to as FAs, are linked to the actin cytoskeleton
and are important structures for maintaining cell shape or modulating the shape as
is necessary during cell motility. Actin stress fibers, for instance, are formed of anti-
parallel bundles of actin filaments that often connect FAs at the front and rear of the
cell to one another and furthermore are able to exert contractile forces on the cell
partially by virtue of their association with the motor protein myosin II (Kaverina
et al, 2002).
Promotion of actin polymerization in membrane protrusion and the creation of
contractile forces leading to FA assembly are largely associated with the small Rho
GTPases (Matozaki et al, 2000). This family includes RhoA, Rac, and Cdc42. Acti-
vation of Rac, in particular, has been implicated in signaling pathways upstream of
the actin nucleation factor Arp2/3 to promote actin polymerization at leading edge
lamellipodia (Cotteret and Chernoff, 2002). The dynamic nature of actin polymer-
ization through Arp2/3 drives cell motility (reviewed in Pollard and Borisy (2003)).
An important aspect of Rho GTPase signaling appears to be the antagonism of
family members against one another (reviewed in Kaverina et al (2002)). Whereas
Rac activation is associated with the formation of small, immature focal complexes
(FXs) and forward protrusion of the lamellipodium, RhoA is associated with FA mat-
uration and stress fiber formation (Nobes and Hall, 1995; Chrzanowska-Wodnicka and
Burridge, 1996; Matozaki et al, 2000). The formation of these complexes in response
to RhoA has been associated with tensile forces exerted on the cell (Chrzanowska-
Wodnicka and Burridge, 1996).
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The coordination of intracellular signals leading to actin polymerization and mem-
brane protrusion is quite complex. Here, a few of the effectors of such signaling have
been reviewed, yet many more effectors are known and many more are probably yet to
be discovered. It is clear, however, that protrusion is an active process influenced not
only by signaling molecules but also by mechanical forces exerted upon the cell and
substratum. It is important to note that these processes are very dynamic and that
as a protrusion extends, it forms multiple FAs at various stages of maturity. Though
thinking of cell motility in three phases may be useful in elaborating our understand-
ing of its mechanics, the elements of one process cannot be easily distinguished from
the other, as is clear when the role of Cdc42 in cortical polarity and protrusion is con-
sidered. RhoA, additionally, is not exclusively an effector of protrusion or retraction.
Principles of retraction
Retraction at the rear of the cell is necessary for the cell body to move forward.
A key step in this process is releasing trailing edge FAs. While protrusion would
not be possible without the establishment of FAs, these trailing edge FAs must be
released in a coordinated manner to assure that the cell does not lose adherence or
stretch itself out beyond its breaking point (Broussard et al, 2008). Contractile forces
exerted at the rear of the cell are important for releasing trailing edge FAs, though
the distribution of force per area is greater at the front of the cell than at the rear
(Kaverina et al, 2002). Stress fibers act as ‘cables’ to create tensile forces that at once
cause maturation of the FAs in the front of the cell, creating strong adhesions there,
but also pull at FAs located in the rear (Riveline et al, 2001). These actomyosin
contractile forces are generated by RhoA and myosin IIa (Riveline et al, 2001).
Whereas disassembly of FAs at the front of the cell tends to occur by a flow of
FA molecules out of the area, trailing edge FAs appear to ‘slide’ or alternately, to
be left behind as a ‘footprint’ when the cell moves on (reviewed in Broussard et al
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(2008)). The mechanics of trailing edge FA retraction have not been studied nearly
as extensively as the disassembly of leading edge FAs, so there is still much to be
learned about this process.
An important question that remains to be fully answered is how the balance of
RhoA signaling is shifted to promote the retraction of FAs at the rear of the cell. In
platelets and CHO cells spread on fibrinogen, a mechanism has been suggested by
which calpain cleavage of β integrin cytoplasmic tails can promote RhoA activity by
releasing c-Src from integrin protein complexes (Flevaris et al, 2007). This is an at-
tractive model as it could explain the sliding mechanism previously described wherein
most of the protein complexes remain intact but detachment of the FA is achieved.
However, it does not easily explain why some trailing edge FAs get left behind as
‘footprints’. It will be interesting to see if the same mechanism holds true for other
cell types adherent to other ECM substrates.
ECM/cell contacts: sites of ECM/actin linkage and pro-motile signaling
The ability of the cell to sense the substratum and orchestrate responses is known
as outside-in signaling and is achieved through integrins (Pozzi and Zent, 2003). In-
tegrins are made up of two subunits, α and β. There are 18 α and 8 β subunits,
which combine to recognize a wide range of ECM ligands from collagen to fibronectin
to proteoglycans (Pozzi and Zent, 2003). When these integrins cluster together at
the ECM, they form plaques known as ECM/cell contacts, which include a subset
of structures including small FXs that occur exclusively at the front of the lamel-
lipodium. These FXs can be highly dynamic, forming as small, punctate adhesions
that turn over rapidly, or mature into larger, oblong FAs (Kaverina et al, 2002). These
mature FAs occur throughout the cell, but especially in the lamella, lamellipodium,
and at the rear of the cell (Kaverina et al, 2002). As FAs mature, they tend to grow
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larger in size until they eventually disassemble. However, some FAs can become in-
corporated under the cell body in the form of elongated fibrillar adhesions that occur
along fibronectin fibrils (Zamir et al, 1999; Volberg et al, 2001). The composition of
each class of ECM/cell contact is slightly different, with small FXs containing early
FA proteins such as paxillin and FAK, but having little zyxin or α-actinin content
(Zaidel-Bar et al, 2003). FAs contain a wide range of proteins depending on their
stage of maturation. These components will be discussed in greater detail under the
subheading ‘Key FA proteins’. The defining feature of fibrillar adhesions is their
tensin content (Zamir et al, 1999).
ECM/cell contacts not only serve to anchor the cell to the substratum, but are
also robust centers of tyrosine phosphorylation and signaling (Zamir et al, 1999). In
fact, a standard method of marking FAs by immunostaining is to use an anti-phospho-
tyrosine antibody. To date, over 100 proteins are known to localize to FAs and are
sometimes referred to as the adhesome (Zaidel-Bar et al, 2003). These proteins serve
scaffolding and signaling functions, linking the actin cytoskeleton to the ECM. The
overall architecture of these adhesions (from the ventral surface of the cell) starts with
the ECM that acts as a ligand for the head groups of α and β integrin receptors. At
the cytoplasmic tail of β integrins, FA proteins such as talin are bound. Talin and/or
paxillin can then serve as scaffolds for the assembly of other FA components such as
vinculin and FAK, which are furthermore bound by proteins such as α-actinin (see
Fig. 1). α-actinin is known to link other FA proteins to actin filament structures, such
as stress fibers. These sites are important structurally, but are in constant flux. Using
spatio-temporal image correlation spectroscopy, it has been shown that elements of
FAs which are in closer proximity to the substratum (such as integrins, talin, and
paxillin) are less dynamic in these structures whereas the structures nearest to the
actin interface such, as α-actinin and actin monomers, dissociate more rapidly (Brown
et al, 2006). Signaling through FAs has been linked to cell survival, whereas loss of
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signaling at FAs is linked to cell death in normal cells, but in transformed cells can
lead to aberrant proliferation, cell motility, and invasion (Vuori and Ruoslahti, 1995;
Vuori et al, 1996). FAs are therefore important for the maintenance of cell shape and
adherence, but are also important mediators of signaling events.
Key FA proteins
As there are greater than 100 proteins known to localize to FAs, I will focus this
review on the most commonly used proteins for marking FAs: paxillin, talin, vinculin,
zyxin, and α-actinin, as well as the non-receptor tyrosine kinases FAK and Src (see
Fig. 1). Several of these proteins have been implicated in binding integrins directly
including: paxillin (Schaller, 2001), FAK, talin, and vinculin (Schaller et al, 1995;
Goldmann et al, 1996).
Paxillin contains several LD motifs at its N-terminus by which it is known to bind
FA proteins such as vinculin, as well as having several LIM domains that are typical
of zinc finger proteins (Schaller, 2001). Use of a β1-integrin peptide to identify FA
proteins bound to integrin suggest that paxillin may also bind to β1-integrin tails
(Schaller et al, 1995). In vivo, paxillin is more likely to bind to α-4 integrin (Schaller,
2001). There is evidence to suggest that the LIM domains of paxillin may serve a
shuttling function, bringing paxillin from FAs to the nucleus where it is thought to
engage in transcriptional regulation (Wang, 2003). However, the biological function
of paxillin transcriptional regulation is poorly understood. As an FA protein, paxillin
is often used as a marker of FAs throughout their lifetime, as its residence has been
confirmed both in nascent and mature FAs (Zamir and Geiger, 2001). For this reason,
paxillin is the most commonly used FA marker in the studies presented in this thesis.
Talin is also known to interact with a variety of FA components including integrins,
vinculin, α-actinin, and actin (Goldmann et al, 1996). Its interaction with integrins
is thought to be phosphorylation-dependent, and its association with FAs can be
7
Figure 1: Molecular architecture of focal adhesions. A schematic of focal adhesion
proteins discussed in this chapter is shown in relationship to their interactions with
one another, integrins, and actin stress fibers (note that these interactions are not
exclusive of other interactions). Integrins are indicated by the symbols α and β.
Figure was drawn based on Mitra et al (2005).
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disrupted by calpain cleavage (Goldmann et al, 1996). Talin plays an important role
in activating integrins. The talin head group binds NPxY motifs in the β integrin
cytoplasmic tail, which causes the heterodimeric complex to shift into the active
conformation (Moser et al, 2009). Microinjection of talin antibody into cells results
in decreased cell spreading and motility, as well as a disruption in FA and stress fiber
formation (Goldmann et al, 1996).
Besides talin, vinculin also associates with paxillin, actin, and α-actinin (Gold-
mann et al, 1996). Vinculin is often thought of as an FA protein that bridges the gap
between integrins and actin filaments. Like paxillin, it is a Src-substrate and becomes
tyrosine phosphorylated at FAs (Goldmann et al, 1996). Consistent with its role as an
FA protein, overexpression of vinculin reduces cell motility (Goldmann et al, 1996).
In contrast, reduced expression leads to a rounded cell shape, increased motility,
decreased adhesion, and less stable lamellipodia and filopodia, though formation of
these structures is not inhibited (Goldmann et al, 1996).
Zyxin is a zinc finger protein with various protein-protein interaction domains
(Beckerle, 1997). Like, paxillin it has been identified as an FA protein with the po-
tential to shuttle to the nucleus and mediate transcription (Wang, 2003). Besides its
three LIM domains in the C-terminus, zyxin also contains a proline-rich region in the
N-terminus followed by a nuclear exit signal. Zyxin is known to interact with Vav and
Ena/Vasp as well as α-actinin. The binding site of zyxin on α-actinin also happens to
be the actin binding site. Consistent with binding of zyxin to the actin cross-linking
protein, α-actinin, zyxin immunostaining not only reveals its localization at FAs, but
also shows zyxin decorating areas of actin filaments closest to FAs (Beckerle, 1997).
The role of tyrosine kinases and their substrates in FAs
FAK, named for its prominent localization to FAs, has long been recognized as a
protein tyrosine kinase that becomes autophosphorylated upon integrin engagement
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(see Hanks and Polte (1997) for review). Though the targeting of FAK to FAs has
been attributed primarily to its interactions with paxillin LD motifs through a C-
terminal FA targeting (FAT) domain (Tachibana et al, 1995; Bertolucci et al, 2005),
in vitro experiments with C-terminal FAK mutants also suggest that FAK may be
able to bind talin (Chen et al, 1995) and β-1 integrin tails (Schaller et al, 1995).
Recent studies have shown that several FA proteins play important roles in me-
diating the overall disassembly of FAs, including paxillin, FAK, Src, and p130Cas
(Webb et al, 2004). Mutation of tyrosine residues on some of these proteins or elim-
ination of their protein tyrosine kinase activity led to comparable defects in paxillin
turnover in FAs than when protein expression was reduced by either knock-down or
knock-out (Webb et al, 2004). FAK and Src are both implicated in regulating FA
disassembly (Volberg et al, 2001; Webb et al, 2004). In FAK -/- or Src, Fyn, Yes
(SYF) -/- MEFs, the rate of paxillin turnover in FAs is decreased by greater than
12-fold (Webb et al, 2004). However, sustained Src tyrosine phosphorylation at FAs
also appears to have negative effects on FA turnover, since increased Src activity at
FAs results in unusually large peripheral adhesions and immobile cells (Siesser et al,
2008). Creation of a FAK/Src chimera wherein the Src kinase domain replaced the
FAK kinase domain, resulted in excessive phosphorylation of several FA proteins in-
cluding paxillin and p130Cas. The cells displayed large FAs with prominent cortical
actin filament bundles joining one another at the periphery. Use of a kinase dead
chimera or a Src inhibitor caused the FAs to return to ‘normal’ states —smaller and
more diffusely spread throughout the cell body (Siesser et al, 2008). These data
suggest that the influence of tyrosine kinases on FA turnover is significant.
FAK appears to be very proximal to integrins at FAs and the clustering of inte-
grins (as demonstrated by causing integrin aggregation on antibody-coated beads) is
sufficient to induce recruitment of FAK to FAs (Miyamoto et al, 1995). Clustering of
integrins was also associated with a rise in tyrosine phosphorylation on these beads
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(Miyamoto et al, 1995). Tyrosine phosphorylation of paxillin appears to be regulated
to a large extent by FAK. Paxillin mutants that cannot bind FAK show significant
reductions in tyrosine phosphorylation (Schaller, 2001). However, Src also appears
to phosphorylate paxillin on tyrosine residues (Schaller, 2001). While Src localizes to
many subcellular compartments, it is clear that a significant number of Src substrates
can be found in FAs.
Discovery of p130Cas and its Primary Structure
P130Cas (Crk-associated substrate) is a Src substrate that functions in integrin
signaling to promote cell motility, invasion, proliferation, and survival (Bouton et al,
2001; Defilippi et al, 2006). p130Cas was first recognized as a prominent tyrosine
phosphorylated protein in cells transformed by retroviral oncogenes v-Crk (Mayer
et al, 1988) and v-Src (Reynolds et al, 1989). The observation that p130Cas inter-
acts directly with the Src homology 2 (SH2) domain of the v-Crk protein (Matsuda
et al, 1990, 1991) contributed to the recognition of SH2 domains as phospho-tyrosine-
binding modules in signal transduction.
Like FAK, p130Cas localizes to FAs and undergoes tyrosine phosphorylation in
response to adhesion (Nojima et al, 1995; Petch et al, 1995; Vuori and Ruoslahti,
1995). Tyrosine phosphorylation of p130Cas occurs preferentially at FAs (Fonseca
et al, 2004) and is enhanced in response to cellular stretching (Sawada et al, 2006).
FAK is thought to be a mediator of p130Cas localization to FAs (Harte et al, 2000),
though prior to the studies presented in this dissertation, no direct evidence for this
claim was presented. Thus p130Cas is a signaling component of the FA protein com-
plex that assembles to bring about cellular responses to integrin engagement.
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Functional domains of p130Cas
The primary structure of p130Cas was first determined from a rat cDNA using
degenerate primers to amplify a peptide that was affinity purified from 3Y1 cells trans-
fected with a v-Crk plasmid (Sakai et al, 1994). An isoform coding an 874 amino acid
protein was detected and analysis of the protein sequence indicated it likely function
as a docking/scaffolding protein due to the observation of several protein-binding mo-
tifs, including a Src-homology 3 (SH3) domain and SH2-binding motifs that conform
to consensus sites for the binding of SH2 adapter protein Crk as well as sites that con-
form to the SH2 domain of Src (Sakai et al, 1994) – see Fig. 2. No domains indicative
of intrinsic enzymatic activity were found, however. Northern blot analysis illustrated
that p130Cas is ubiquitously expressed in rat tissues, with higher expression levels
seen in the brain, lung, intestine, kidney, and testis (Sakai et al, 1994).
The Src-homology 3 domain
P130Cas was independently identified in a two-hybrid screen for mouse proteins
that interact with FAK (Polte and Hanks, 1995). A Src homology 3 (SH3) domain
at the N- terminus of p130Cas mediates the FAK interaction, by interacting with the
PR-1 and to a lesser extent the PR-2 of FAK (Polte and Hanks, 1995; Harte et al,
1996; Polte and Hanks, 1997). The interaction of p130Cas with FAK and other SH3
binding proteins will be discussed at greater length in this chapter in the section:
“p130Cas binding partners”.
A proline-rich region follows the SH3 domain, spanning ∼ 40 amino acid residues.
No known function has been attributed to this domain and therefore, this domain
will not be discussed at any greater length.
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Figure 2: Illustration of p130Cas domains. The primary structure of p130Cas is
represented to scale from the N-terminus to C-terminus. “SH3” corresponds to the
Src-homology 3 domain, “Pro” is for proline-rich domain, “SD” is for substrate do-
main, “SER” is for serine-rich domain, “SBD” is for Src binding domain including
the motifs for the Src SH2 and SH3 binding, and “CCH” is for the Cas-family C-
terminal Homology domain. Measurements are based on information obtained from
NCBI Accession Number Q61140 (p130Cas from mus musculus). The SD includes 15
phospho-tyrosine sites included in YxxP motifs at residues 119, 132, 169, 183, 196,
238, 253, 271, 291, 310, 331, 366, 376, 391, and 414 (Shin et al, 2004). The CCH
domain is designated based on Cas-family protein sequence alignments (see Chapter
3, Fig. 9 for details.)
The Substrate Domain
The major sites of p130Cas tyrosine phosphorylation lie scattered about in the
∼ 300 amino acid residue substrate domain (SD) — see Fig. 2 — located in the N-
terminal half of the protein (Sakai et al, 1994, 1997). These 15 YxxP motifs (Sakai
et al, 1997), most of which have been detected as in vivo sites of tyrosine phosphory-
lation (Luo et al, 2008; Rush et al, 2005) include 9 YDxP motifs that, upon tyrosine
phosphorylation, best match the optimal phospho-tyrosine binding motifs for SH2 do-
mains of the SH2/SH3 adapter proteins Crk and Nck (Cantley and Songyang, 1994).
The 9 YDxP tyrosines are among 10 p130Cas SD YxxP sites known to be phospho-
rylated by Src in vitro (Shin et al, 2004), and the recruitment of Crk (Sakai et al,
1994) and Nck (Schlaepfer et al, 1997) to these sites has been documented. With
their capacities to dock efficiently to sites of tyrosine phosphorylation in the p130Cas
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SD, combined with their abilities to promote downstream pathways leading to actin
assembly (reviewed in Feller (2001); Buday et al (2002)), adapters of the Crk and
Nck families emerged as key downstream effectors of p130Cas in the regulation of cell
motility and invasion. The association of p130Cas and these SH2 adapter proteins
will be discussed at greater length in the section of this chapter entitled “p130Cas
binding partners”.
The Serine-rich Domain
In addition to these sites of tyrosine phosphorylation, p130Cas also has a serine-
rich (SER) domain — see Fig. 2 — whose phosphorylation has been associated with
its ability to bind the 14-3-3 protein (Garcia-Guzman et al, 1999), which will be dis-
cussed at greater length in this chapter under the heading of “p130Cas binding part-
ners.” NMR studies have shown that the SER domain folds into a four helical bundle
similarly to the FAK FAT domain, but also has novel features indicative of protein-
protein binding characteristics near the C-terminal end of the domain (Briknarova
et al, 2005). Significant serine phosphorylation of p130Cas has been documented by
phosphopeptide mapping when fibroblasts are subjected to fibronectin replating for
3 hours (Schlaepfer et al, 1997).
Interestingly, an increase in serine phosphorylation of p130Cas (and concomitant
loss of tyrosine phosphorylation) has also been documented when cells are undergoing
mitosis, a process shared by FA proteins FAK and paxillin (Yamakita et al, 1999).
Interestingly, recovery of tyrosine phosphorylation after mitosis occurs in a similar
time course for p130Cas, FAK, and paxillin, with the highest levels of tyrosine phos-
phorylation occurring first on FAK, then paxillin, and last on p130Cas (Yamakita
et al, 1999). This coordination of tyrosine phosphorylation may be indicative of the
dynamics with which these proteins repopulate FAs after mitosis. It would therefore
be interesting to see whether this time course is a general feature of how these FA
14
proteins become tyrosine phosphorylated or if this time course only occurs as a result
of exit from mitosis.
Recently, a mechanism has been suggested by which AND-34/BCAR3 can pro-
mote serine phosphorylation of p130Cas in breast cancer cells (Makkinje et al, 2009).
Serine-phosphorylation of p130Cas appears to be elevated in estrogen receptor (ER)
positive breast cancer cells in comparison to ER negative breast cancer cells (Makkinje
et al, 2009). Serine phosphorylation of p130Cas does not require direct binding
of AND-34 to p130Cas, but appears to be reliant on an SH2 and serine-rich re-
gion in AND-34 for the interaction, which induces p130Cas to run as a slower mi-
grating band during SDS-PAGE (Makkinje et al, 2009). Serine phosphorylation of
p130Cas occurs independently of Src and FAK phosphorylation, although abrogating
the FAK/p130Cas interaction leads to a reduction in the amount of p130Cas that is
serine phosphorylated without completely abrogating its phosphorylation (Makkinje
et al, 2009). Cell adhesion and the integrity of the actin cytoskeleton, however, is
necessary to induce serine phosphorylation of p130Cas (Makkinje et al, 2009). The
kinase responsible for this phosphorylation has not yet been identified, but might
generate insight into the mechanisms by which p130Cas can induce anti-estrogen re-
sistance in breast cancer (see section in this chapter entitled “The roles of p130Cas
in cancer” for more details).
The Src-binding Domain
In addition to the FAK/Src bridge recruiting Src to p130Cas, two motifs near the
p130Cas C-terminus have been characterized as the Src-binding domain (Fig. 2). At
least one SH2-binding site in p130Cas was predicted to bind the Src SH2 domain
(Sakai et al, 1994; Nakamoto et al, 1995). The contribution that the SH2-binding site
makes in the recruitment of Src to p130Cas is controversial, however. The YDYV
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motif in the SBD contributes negligibly to the interaction with Src while the polypro-
line region of p130Cas is a more likely mediator of Src binding, through the Src
SH3 domain (Burnham et al, 2000; Pellicena and Miller, 2001; Ruest et al, 2001).
This polyproline region stands alone from the aforementioned proline-rich region and
starts near the C-terminus at residue 639 – see Fig. 2. The sequence of this motif
is RPLPSPP. The binding of Src to p130Cas through the SBD has also been linked
to enhanced c-Src activity (Burnham et al, 1999, 2000; Pellicena and Miller, 2001).
The p130Cas SBD interaction can compete with the inhibitory intramolecular inter-
actions of Src to bring the kinase into its open and active conformation and this may
be primarily achieved through the Src SH3 interaction with p130Cas polyprolines
(Burnham et al, 2000; Pellicena and Miller, 2001).
The Cas-family C-terminal Homology Domain
Though it is one of the most conserved regions amongst p130Cas family members,
the functions of the Cas-family C-terminal Homology Domain (CCH) are poorly un-
derstood. This region, which includes the last 141 amino acid residues of p130Cas,
has been noted as an interaction domain for NSP family proteins (see section entitled
“CCH domain interacting proteins”), but has also been attributed with a number of
functions ranging from transcriptional regulation to FA targeting (see Bouton et al
(2001) for a review). To better understand the importance of this domain, the greater
Cas-family must first be discussed.
Cas-family members
p130Cas is the founding member of the Cas family of proteins that, in mammals,
also includes HEF-1/Cas-L/NEDD9, Efs/Sin (reviewed in(O’Neill et al, 2000), and
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HEPL (Singh et al, 2008). While p130Cas is expressed ubiquitously, HEF-1/Cas-
L/NEDD9, Efs/Sin, and HEPL have restricted tissue distributions. Additionally, a
p130Cas homolog has been found in Drosophila melanogaster, which shows a surpris-
ing level of domain conservation, especially in the N- and C-terminal domains (Huang
et al, 2007). Fig. 3 illustrates the many common features of these Cas-famioly mem-
bers, as well as demonstrating the variability. Notably, the number of and consensus
motifs of the SD domains vary amongst family members. Unlike most of the Cas-
family members, HEF-1 lacks the RPLSPP motif for binding the Src SH3 domain
(?). While the SH3 domain is one of the most conserved domains amongst most of
the Cas-family members, HEPL displays the least primary sequence conservation of
this domain (Singh et al, 2008).
HEF-1/Cas-L/NEDD9
Human enhancer of filamentation 1 (HEF1) was identified by screening a HeLa
cDNA expression library for genes that induced pseudohyphal growth in Saccha-
romyces cerevisiae (Law et al, 1996). The HEF1 C-terminus was once thought to
contain a divergent helix-loop-helix motif with similarities to transcription factors
such as MyoD (Law et al, 1999). Recent data from this and other research groups
now suggest that this area is not in fact a helix-loop-helix motif and may instead fold
as either a β-sheet turn α-helix (Singh et al, 2008) or as helices 2 and 3 of a four
α-helical bundle (Garron et al, 2009).
HEF1 is processed into a variety of different isoforms post-translationally (Law
et al, 1998, 2000). Tyrosine phosphorylation of HEF1 results in a shift of the original
band (105 kDa) to a slower migrating band at 115 kDa. The protein can furthermore
be processed into smaller fragments by caspase cleavage in vivo. The appearance of a
55 kDa band (consisting of the N-terminal half of the protein) during mitosis has been
correlated with a role for HEF1 in the cell cycle where this fragment associates with
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the mitotic spindle (Law et al, 1998), whereas the appearance of a 28 kDa fragment
(that consists mostly of the conserved C-terminus) has been linked to a role for HEF1
in mediating apoptosis (Law et al, 2000). Accumulation of the 28 kDa product was
also correlated with JNK phosphorylation, which was found to colocalize with a GFP
fusion of this C-terminal HEF1 product in FAs.
Considering the conservation of HEF1 and p130Cas domains, it is not surprising
that HEF1 was found to coimmunoprecipitate (CoIP) with FAK and its localization
to FAs was confirmed by immunostaining (which also revealed some nuclear and cy-
toplasmic localization) (Law et al, 1996). Though Law et al (1996) did not clearly
demonstrate an association between HEF1 and v-Crk, an association between HEF1
and Crk1 was later shown in cells wherein leukomogenesis was induced by BCR/ABL
(de Jong et al, 1997). Indeed, HEF1 was independently identified in lymphocytes as
Cas-L (lymphocyte-type Cas), a protein implicated in integrin signaling (Minegishi
et al, 1996). It was also identified in melanocytes as a gene conferring metastatic
properties in melanomas and was renamed NEDD9 in that context (Kim et al, 2006).
Therefore, HEF1 appears to share some structural features and signaling functions
with p130Cas, yet also exerts some divergent functions.
Efs/Sin
Expression of Efs, “Embryonic fyn substrate”, is primarily restricted to embryonic
tissues such as the embryo and placenta, but also to a lesser extent in skeletal muscle,
brain, and the brainstem (Ishino et al, 1995). Efs was discovered by screening a cDNA
expression library with the SH3 domain of Fyn, though it was also found to interact
with Yes (both are SFKs). Further study revealed that the protein spans 560 amino
acids and runs as an 83 kDa band (despite a predicted mass of only 59 kDa) (Ishino
et al, 1995).
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Figure 3: Protein sequence alignment of Cas-family members. Protein Sequence align-
ments were performed by ClustalW on UniProt website with sequences of p130Cas,
Mouse Uniprot ID Q61140; HEF1, Mouse Uniprot ID O35177; EFS, Mouse Uniprot
ID Q64355; DmCAS, Drosophila Uniprot ID Q7KVE5; HEPL, Mouse Uniprot ID
Q08EC4. Conserved domains are indicated by color: the SH3 domain (green), YxxP
motifs in the SD (yellow), features of the SBD (purple), and the CCH domain (cyan).
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Efs was separately identified as Sin, “Src interacting or signal integrating protein”,
in a screen to identify proteins that interacted with the Src SH3 domain (Alexan-
dropoulos and Baltimore, 1996). Expression of a short sequence of Sin including a
polyproline region led to an increase in c-Src activation and increased phosphorylation
of the enolase substrate (Alexandropoulos and Baltimore, 1996). The ability of Sin to
promote c-Src activation was further increased when a Sin expression construct was
expanded to include the SH3 domain, suggesting that like p130Cas, Sin interactions
with Src may be enhanced through binding FAK family proteins (Alexandropoulos
and Baltimore, 1996). Crk binding to Sin appears to be Src-dependent (Alexan-
dropoulos and Baltimore, 1996) and has been implicated in neurite outgrowth as a
result of EGF stimulation in PC12 cells (Yang et al, 2002). The effects of Sin on
neurite outgrowth through EGF were found to be dependent upon receptor protein
tyrosine phosphatase-α and the Sin SD (Yang et al, 2002). In T lymphocytes, Sin
has been shown to modulate T-cell receptor signaling by sequestering signaling com-
ponents such as PLCγ (Xing et al, 2004). Small variations in the Efs/Sin SD and its
restricted expression may further differentiate its signaling capacities from p130Cas.
HEPL
HEPL (HEF1-Efs-p130Cas-like) was recently identified in a BLAST search for
proteins that have similar primary structure features to Cas-family members (Singh
et al, 2008). HEPL exhibits a similar distribution in tissues to HEF-1 (especially
in the lung and spleen) and mRNA levels of HEPL were most readily detectable in
ovarian and leukemia cell lines (Singh et al, 2008). The HEPL protein consists of 786
amino acids and like other Cas-family members and secondary structure alignment
of HEPL, Efs, HEF1, and p130Cas C-terminal sequences suggests a structure with
three α-helices and one β-sheet occurring between the first and third helices (Singh
et al, 2008).
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Despite lower conservation of the SH3 domain sequence, yeast two-hybrid con-
firmed interaction of the HEPL SH3 domain with FAK. HEPL localization to FAs
was also observed. Depletion of HEPL was correlated with a reduction in cell spread-
ing and cell motility, though these effects appear to be intermediate to those seen in
the siRNA scramble control and the HEF1 siRNA population. No significant effects
on proliferation or apoptosis were observed in cell populations treated with HEPL
siRNA (Singh et al, 2008). This is the first and currently only study on HEPL.
Clearly, greater research is needed to elucidate the functions of this protein.
DmCAS
DmCas was found in a bioinformatic search for genes in Drosophila melanogaster
with similarities to p130Cas (Huang et al, 2007). Sequencing of the cDNA from a
candidate gene was predictive of a 793 amino acid protein with a primary struc-
ture similar to Cas family members including an SH3 domain (see Fig. 3). Study of
Drosophila larvae revealed that DmCAS is highly expressed in the nervous system
and loss-of-function (LOF) mutants as well as gain-of-function (GOF) mutants ex-
hibit neuronal defasciculation defects, wherein the motor neurons fail to branch out
from the fascicle (Huang et al, 2007). These defects mimic α1-integrin LOF and GOF
mutants. It will be interesting to see whether DmCAS will exhibit similar signaling
functions to mammalian Cas-family members.
p130Cas acts as a docking site for multiple binding proteins
Though p130Cas has no intrinsic enzymatic activity, it exerts influence on a myr-
iad of signaling pathways by virtue of its protein docking properties. Known binding
partners of p130Cas are discussed in this section, with those binding the N-terminus
of the protein discussed first (see Table 1).
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Table 1: Known p130Cas binding partners and interaction domains
Cas Domain Binding Partner Site Bound References
SH3
FAK
PR
(Polte and Hanks, 1995, 1997)
PYK2 (Astier et al, 1997)
FRNK (Harte et al, 1996)
PTP1B (Liu et al, 1996)
C3G (Kirsch et al, 1998)
CMS (Kirsch et al, 1999)
PR-39 (Chan and Gallo, 1998)
PTP-PEST (Garton et al, 1997)
SD
Crk
SH2
(Sakai et al, 1994)
Nck (Schlaepfer et al, 1997)
SHIP-2 (Prasad et al, 2001)
SER 14-3-3 K49 (Garcia-Guzman et al, 1999)
SBD
SFKs SH2,3 (Nakamoto et al, 1995, 1997)
Neph SH3 (Donaldson et al, 2000)
PI3-K SH3 (Li et al, 2000)
CCH
AND-34 GEF (Gotoh et al, 2000)
Chat GEF (Sakakibara and Hattori, 2000)
Ajuba Pre-LIM (Pratt et al, 2005)
SH3 domain interactions
At its N-terminus, p130Cas has an SH3 domain known to associate with FAK
(Polte and Hanks, 1995), the FAK family member protein tyrosine kinase 2 — PYK2
(Astier et al, 1997), guanine nucleotide exchange factor C3G (Kirsch et al, 1998), Cas-
ligand with multiple SH3 domains — CMS (Kirsch et al, 1999), antimicrobial peptide
PR-39 (Chan and Gallo, 1998), and the protein tyrosine phosphatases PTP1B (Liu
et al, 1996) and PTP-PEST (Garton et al, 1997). The interaction between p130Cas
and FAK was determined by yeast two-hybrid screening using a C-terminal truncation
of FAK as bait (Polte and Hanks, 1995). Mutation of a PR region in the bait to Ala
residues abrogated the interaction (Polte and Hanks, 1995). The interaction between
p130Cas and FAK was later shown to occur primarily through the PR-1 and partly
through PR-2 region of FAK (Polte and Hanks, 1997). Despite the direct interaction of
the p130Cas SH3 domain with FAK, tyrosine phosphorylation of p130Cas is attributed
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to SFKs (Hamasaki et al, 1996; Vuori et al, 1996; Sakai et al, 1997). Nevertheless,
FAK serves an important role in the efficient tyrosine phosphorylation of p130Cas
by acting as a scaffold to recruit Src to p130Cas by virtue of the Src SH2 domain
interaction with the FAK autophosphorylation site Y397 (Ruest et al, 2001).
PYK2 was found in association with p130Cas by CoIP after simulating integrin
ligation using a β-1 integrin monoclonal antibody (Astier et al, 1997). The interaction
was found to be dependent on cytoskeletal integrity, as cytochalasin D treatment
abrogated the ability of the proteins to bind one another (Astier et al, 1997).
Association of C3G with p130Cas binding partner CrkII was previously docu-
mented (Vuori et al, 1996), yet p130Cas can also bind C3G directly through its SH3
domain (Kirsch et al, 1998). Mapping studies of C3G revealed that the binding site
for the p130Cas interaction is in fact a different motif than the one needed for the
C3G-CrkII association (Kirsch et al, 1998). Mutation of C3G amino acid residues 287
and 289 abrogated the association (Kirsch et al, 1998). Like PTP1B and PTP-PEST,
these studies confirm that the p130Cas SH3 domain preferential binds to PPxP motifs
(Kirsch et al, 1998). C3G activity has been shown in relationship to Rap1 (Gotoh
et al, 1995) and R-Ras (Gotoh et al, 1997). Further studies are needed to understand
how C3G influences aspects of p130Cas signaling.
CMS, like C3G, was identified by yeast two-hybrid with the p130Cas SH3 domain
as bait (Kirsch et al, 1999). CMS contains three SH3 domains followed by a proline-
rich region through which the p130Cas SH3 domain is thought to bind (Kirsch et al,
1999). IP experiments with a transfected p130Cas SH3 domain or full-length pro-
tein confirmed the interaction of CMS with p130Cas in HEK-293 cells (Kirsch et al,
1999). By immunostaining experiments, Kirsch et al (1999) found that CMS localizes
primarily to the cytoplasm in a punctate manner (which was not seen when a trun-
cated version of the protein expressing only the SH3 domain or lacking the C-terminal
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coiled-coil domain were expressed). Upon stimulation with phorbol 12-myristate 13-
acetate (PMA), however, CMS colocalized with actin in membrane ruﬄes similarly
to p130Cas (Kirsch et al, 1999). Kirsch et al (1999) noted that p130Cas and CMS
colocalized in membrane ruﬄes as ‘data not shown’.
PR-39 is an antimicrobial peptide (endogenous, non-synthetic) that has been
shown to have anti-LPA properties and stimulates wound-healing (Chan and Gallo,
1998). An interaction between the p130Cas SH3 domain and PR-39 was found when
full-length p130Cas expressed in endothelial cells was CoIPed with PR-39 (Chan and
Gallo, 1998). Fractionation experiments showed that this interaction was most robust
in the cytoskeletal fraction (Chan and Gallo, 1998). These data suggest another mech-
anism by which p130Cas may regulate microbial pathogenesis by altering the actin
cytoskeleton (see the subheading “Pathogenesis” in this chapter for more details).
PTP1B, a protein tyrosine phosphatase, associates with p130Cas by virtue of one
of its two proline-rich regions (located around residues 300-320), which fits the con-
sensus sequence for the p130Cas SH3 domain (Liu et al, 1996). Mutation of the first
two residues in this sequence (PPRP) abrogated the ability of p130Cas to CoIP with
PTP1B (Liu et al, 1996). Liu et al (1996) concluded that the ability of PTP1B to as-
sociate with p130Cas was not dependent on p130Cas tyrosine phosphorylation (since
p130Cas and PTP1B still CoIPed in non-transformed cells wherein p130Cas tyrosine
phosphorylation was not detected). They did, however, find that overexpression of
PTP1B in cells that were v-Crk transformed resulted in a reduction of p130Cas phos-
phorylation (Liu et al, 1996). These data make PTP1B an interesting candidate for
the phosphatase that regulates the absence of p130Cas phosphorylation in the cyto-
plasm. It would be interesting to see if the association of p130Cas with PTP1B truly
occurs in the absence of its tyrosine phosphorylation (it is now known that in order to
detect p130Cas phosphorylation in non-transformed cells by immunoblotting, sodium
vanadate treatment must be used to inhibit phosphatase activity — see Fonseca et al
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(2004)). Use of λ phosphatase to treat cell lysates prior to IP might offer such insight,
for example.
Garton et al (1996) demonstrated that p130Cas and PTP-PEST interact via the
p130Cas SH3 domain to further enhance the ability of PTP-PEST to dephosphory-
late the protein. Previous studies showed that PTP-PEST dephosphorylates p130Cas
on tyrosine residues, though dephosphorylation of p130Cas on tyrosine by the PTP-
PEST catalytic domain was slightly less efficient in comparison to the PTP-1B cat-
alytic domain (Garton et al, 1996). IP experiments demonstrated a dose-dependent
interaction between the p130Cas SH3 domain and the C-terminal region of PTP-
PEST (Garton et al, 1996). PTP-PEST contains two proline-rich regions at the
C-terminus, yet inclusion of the first proline-rich region alone was sufficient for the
p130Cas interaction (Garton et al, 1996). While interaction of PTP-PEST with
p130Cas through the catalytic domain appears to be pTyr- dependent (pervanadate
treatment increases the amount of protein CoIPed), the interaction of the p130Cas
SH3 domain with PTP-PEST is not affected by pTyr content (Garton et al, 1996).
While CoIP experiments with full-length PTP-PEST and p130Cas were unsuccessful
(presumably because the interaction between PTP-PEST and p130Cas is so tran-
sient), use of a PTP-PEST mutant D199A (which has much lower catalytic activity)
allowed the investigators to detect p130Cas and PTP-PEST in complex (Garton et al,
1996).
These results present an interesting mechanism by which the SH3 domain of
p130Cas can regulate its own tyrosine phosphorylation and dephosphorylation. Since
the SH3 domain is also the recruitment site for FAK, it would be interesting to study
the dynamics of FAK and PTP-PEST interaction with p130Cas in live cells with
FRET probes. In this manner, it would be possible to see whether p130Cas recruits
PTP-PEST to FAs where it exchanges its interaction with FAK for PTP-PEST or
whether the PTP-PEST interaction occurs only in the cytoplasm.
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Substrate domain (SD) interactions
When p130Cas is phosphorylated at the SD by Src and its family members
(Nakamoto et al, 1995), it is not only able to recruit Crk and Nck, but also in-
ositol phosphatase SHIP-2 (Prasad et al, 2001). The association of p130Cas with
Crk and Nck has been linked to Rac activation and cell motility (Chodniewicz and
Klemke, 2004). P130Cas can bind CrkII via 10 of its 15 YxxP motifs (Shin et al,
2004). Association of p130Cas with Crk is implicated in variety of signaling path-
ways. These aspects will be further elaborated in the section of this chapter entitled
“p130Cas signaling paradigms”. Nck1 associates with the p130Cas SD in response
to fibronectin replating (Schlaepfer et al, 1997). Interestingly, the sites indicated for
Nck association are within the first 6 YxxP motifs of the SD (Schlaepfer et al, 1997),
whereas the Crk binding sites are indicated in the last 10 YxxP sites (Shin et al,
2004). Nck SH2 binding of p130Cas after cells are stimulated with platelet-derived
growth factor (PDGF) has also been noted and is linked to cell motility (Rivera et al,
2006).
The Src-Homology 2 containing inositol phosphatase-2 SHIP-2 (or inositol polyphos-
phate phosphatase-like 1 (INPPL1)) interaction with tyrosine phosphorylated p130Cas
is dependent upon its SH2 domain (Prasad et al, 2001). The interaction is further-
more regulated by cellular adhesion as evidenced by the lower amount of protein
CoIPed when HeLa cells are trypsinized versus adherent or replated on fibronectin
(Prasad et al, 2001). Upon replating, a faster migrating SDS-PAGE band of p130Cas
was found in association with SHIP-2 in whole cell lysates from HeLa cells that was
abrogated when cells were treated with protease but not caspase inhibitors (Prasad
et al, 2001). SHIP-2 was furthermore found to colocalize with paxillin in FAs, which
was dependent on the SH2 domain and cell spreading was reduced in cells express-
ing a mutant form of SHIP-2 wherein the catalytic domain was mutated (Prasad
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et al, 2001). These data suggest that SHIP-2 may associate with multiple species
of the p130Cas protein to modulate separate processes. Perhaps the catalytic do-
main mediates a role for p130Cas in membrane ruﬄes and cell spreading, whereas
the SH2 interaction is more important for p130Cas signaling in FAs. Alternately,
the SH2 interaction with p130Cas may serve as a negative feedback mechanism by
which phosphorylated p130Cas can be recognized by SHIP-2 at FAs and can then be
shuttled into membrane ruﬄes for eventual targeting to the proteasome.
Though protein motifs mediating the interaction of p130Cas with the Ras effector
protein Grb2 are not known, it appears that the association of p130Cas and Grb2
is pTyr-dependent in cells treated with epidermal growth factor (EGF) (Wang et al,
2000). Grb2 IP in EGF, but not fibroblast growth factor (FGF) treated cells, re-
sulted in p130Cas CoIP (Wang et al, 2000). Expression of a receptor protein tyrosine
phosphatase, LAR, resulted in dissociation of p130Cas and Grb2 and also resulted in
reduced appearance of a pTyr band in the 130 kDa range (Wang et al, 2000).
Serine-rich domain interactions
The p130Cas SER domain has been shown to interact with 14-3-3ζ protein both in
vitro and in vivo (Garcia-Guzman et al, 1999). Expression of a mutant form of 14-3-3
wherein the Lys 49 residue was mutated to Asp, calf alkaline phosphatase treatment
of cell lysates, or SER domain deletion all resulted in dissociation of these proteins
(Garcia-Guzman et al, 1999). The binding of p130Cas with 14-3-3 was increased
in cells that were allowed to adhere to fibronectin in comparison to those plated
on polylysine or left in suspension (Garcia-Guzman et al, 1999). Immunostaining
of p130Cas and 14-3-3 demonstrated strong colocalization in membrane ruﬄes of
spreading cells as well as in the cytosol of well-spread cells (Garcia-Guzman et al,
1999). Slight FA localization of 14-3-3 was also seen by immunostaining using vinculin
as an FA marker (Garcia-Guzman et al, 1999). These results are interesting since the
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function of p130Cas serine phosphorylation is still poorly understood.
14-3-3 proteins are known to coordinate the formation of a number of different
protein complexes. It would be interesting to know what other proteins constitute the
p130Cas/14-3-3 complex and whether or not other 14-3-3 isoforms similarly interact
with p130Cas. In particular, it would be interesting to know whether or not 14-3-3 is
important in bringing AND-34 into complex with p130Cas for serine phosphorylation,
since the interaction of p130Cas and AND-34 after serine phosphorylation has been
shown to occur indirectly (Makkinje et al, 2009).
Src-binding domain (SBD) interactions
Several other proteins are known to bind to the Src-binding domain (SBD). These
proteins include: the SFKs Src, Fyn, Yes, Lck (Nakamoto et al, 1995), Lyn and Hck
(Manie et al, 1997), as well as Nephrocystin (Donaldson et al, 2000) and PI3-K (Li
et al, 2000). The RPLPSPP motif is known to bind the SH3 domain of Src, whereas
the the YDYV motif at residue 668 is able to bind the Src SH2 domain (Nakamoto
et al, 1997).
In kidney epithelial cells, studies by Donaldson et al (2000) showed that p130Cas
localizes to cell-cell contacts, colocalizing with E-cadherin. CoIP experiments showed
a direct interaction between p130Cas and the SH3 domain of Nephrocystin (Donald-
son et al, 2000). In MDCK cells, p130Cas localizes prominently to FAs instead of
cell-cell adhesions, leading the authors to suggest that in subconfluent cells, p130Cas
localizes to FAs, establishing contact with the ECM. As the cells then become more
confluent and begin to contact one another, p130Cas may be involved in integrin-
mediated orientation of apical-basal cell polarity (Donaldson et al, 2000).
As a result of adenovirus entry, p130Cas becomes heavily tyrosine phosphorylated
and becomes associated with the p85 subunit of PI3-K (Li et al, 2000). The SBD
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appears to mediate the interaction of p130Cas and PI3-K, as site-directed mutagene-
sis of the RPLPP motif in the p130Cas SBD is sufficient to abrogate the interaction.
This mechanism appears to be regulated by integrin signaling through the actin cy-
toskeleton (Li et al, 2000; Armulik et al, 2004).
CCH domain interacting proteins
NSP family member Chat (also known as NSP3 or SHEP1) has been shown to
interact with p130Cas through its conserved C-terminus (Sakakibara and Hattori,
2000). Chat localizes with p130Cas along actin filaments and membrane ruﬄes,
as ascertained by immunostaining (Sakakibara and Hattori, 2000). Another NSP
family member, AND-34 (also known as BCAR3 or NSP2) localizes with p130Cas
in lamellipodia and membrane ruﬄes (Riggins et al, 2003). Mapping studies of
the p130Cas/AND-34 interaction revealed a necessity for the C-terminal domain of
p130Cas (Gotoh et al, 2000). Additional studies showed that mutation of residue 791
in p130Cas disrupts AND-34 binding to p130Cas (demonstrated by CoIP), suggesting
that AND-34 binds directly to this residue (Gotoh et al, 2000). The importance of
this residue in the p130Cas/AND-34 interaction has been futher supported by the
observation that AND-34 binding to HEF-1 occurs through the same binding mo-
tif (Garron et al, 2009). Mutation of this residue does not, however, disrupt the
ability of HEF-1 to localize to FAs (Garron et al, 2009). Indeed, it was previously
shown that even though AND-34 colocalizes at lamellipodia and membrane ruﬄes
with myc-tagged p130Cas, FA staining is not observed for AND-34 (Riggins et al,
2003).
NSP1 is also thought to associate with p130Cas through the C-terminal domain,
since the GEF domain (by which Chat and AND-34 bind p130Cas) is well-conserved
amongst family members (Alexandropoulos and Regelmann, 2009). However, map-
ping studies to confirm these interactions between p130Cas and NSP1 have not yet
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been published. Despite this limitation, it is known that p130Cas associates with
NSP1 (Lu et al, 1999).
In addition to these NSP family members, a zyxin family member, Ajuba, has also
been identified as a CCH-interacting protein (Pratt et al, 2005). Evidence for the di-
rect interaction between p130Cas and Ajuba was shown through mapping studies
wherein a p130Cas mutant lacking the C-terminal domain was not able to associate
with Ajuba in comparison to WT (Pratt et al, 2005). The Pre-LIM region of Ajuba
was identified as the interacting domain through another series of CoIPs and com-
petitive binding experiments (Pratt et al, 2005). Though not indicated as an integral
protein for the association of p130Cas with FAs, Ajuba may play an important role
in localizing p130Cas to lamellipodia and membrane ruﬄes (Pratt et al, 2005). Im-
munocytochemistry experiments with Ajuba -/- cells reveal normal FA formation but
greatly reduced lamellipodial extension and membrane ruﬄing (40% less than WT).
Cell motility and p130Cas localization defects were reversible in Ajuba -/- cells by ex-
ogenous expression of Rac1, indicating that Rac1 activation downstream of p130Cas
may be important for this particular pathway and that Ajuba may signal upstream of
Rac1. Ajuba -/- cells co-transfected with WT Ajuba and a p130Cas mutant lacking
the C-terminal domain were unable to stimulate lamellipodial extension in compari-
son to cells expressing WT p130Cas (Pratt et al, 2005).
p130Cas functional roles and signaling paradigms
By virtue of its docking properties, p130Cas regulates a large variety of signaling
pathways and cellular functions. Here, I will present a review of known p130Cas sig-
naling paradigms and various cellular functions that these affect. The major mode of
p130Cas signaling is through the phosphorylation of tyrosine residues in its SD, which
occurs as a result of a number of stimuli such as: integrin engagement (Nojima et al,
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1995; Petch et al, 1995; Vuori and Ruoslahti, 1995), stimulation by growth factors
such as EGF, PDGF, and insulin, antigen stimulation such as LPA and lymphocyte
function-associated antigen-1 (Petruzzelli et al, 1996; Casamassima and Rozengurt,
1997, 1998), neuropeptides such as bombesin (Casamassima and Rozengurt, 1997;
Rozengurt, 1998), glucose stimulation in pancreatic β cells (Lee et al, 2004), and
signaling from the urokinase-type plasminogen activator receptor (Smith et al, 2008).
Central to many of p130Cas signaling paradigms is the association of p130Cas with
Crk (Chodniewicz and Klemke, 2004), which is summarized in Fig. 4.
Figure 4: The coupling of p130Cas to CrkII is central to several p130Cas signaling
paradigms. Signaling through p130Cas/CrkII leads to actin assembly pathways in-
volved in cell survival as well as cell motility, invasion of cancer cells, and phagocytosis
of pathogens. Figure is partially based on Chodniewicz and Klemke (2004).
Functional roles of p130Cas in the heart and vasculature
Cas -/- mice die of severe cardiac abnormalities at embryonic day 12.5 wherein
the heart consists of a thin myocardium and dilated blood vessels (Honda et al, 1998).
Electron microscopy revealed that the myofibrils and Z-discs in the myocardium of
32
Cas -/- mice show extensive disorganization in comparison to WT littermates (Honda
et al, 1998). Cas -/- MEFs analyzed for their actin organization by phalloidin staining
showed a reduction in stress fiber formation, although FA formation was documented
as indicated by vinculin immunostaining (Honda et al, 1998). p130Cas and FAK have
been further implicated in heart development as they are known to localize to Z-lines
in the myocardium wherein disassociation of p130Cas and FAK can cause sarcomeric
disorganization (Kovacic-Milivojevic et al, 2001, 2002). Arterial contraction in re-
sponse to serotonin is also regulated in part by p130Cas (Ogden et al, 2006). Arterial
contraction leads to p130Cas tyrosine phosphorylation in a Src- and actin-dependent
manner (Ogden et al, 2006). Use of a serotonin inhibitor reduces p130Cas tyrosine
phosphorylation and arterial contraction is reduced by p130Cas knock-down (Ogden
et al, 2006).
Functional roles of p130Cas in the brain
In addition to finding heart defects in Cas -/- mouse embryos, Honda et al (1998)
observed a decrease in brain size. Later studies showed that WT mice exhibit elevated
levels of p130Cas in the cerebellum around 7 days postpartum (Huang et al, 2006).
Coincident with these elevated levels of protein are elevated levels of p130Cas tyrosine
phosphorylation (Huang et al, 2006). These findings are perhaps not surprising, since
p130Cas is a major Src substrate and Src activity is elevated in the cerebellum of de-
veloping rats at levels 6-10 times higher than is usually seen in fibroblasts (Cartwright
et al, 1988). This trend of elevated activity is seen even though the expression of Src
remains relatively constant throughout cerebellar development — 1-2 times higher
than fibroblasts (Cartwright et al, 1988).
Knockdown of p130Cas with siRNA in cerebellar granule cells results in significant
defects in growth cone elongation (Huang et al, 2006). Similar defects in growth cone
elongation were seen when cells were transfected with p130Cas SD deletion mutants,
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but not when p130Cas constructs containing SH3 or SBD mutations were expressed
(Huang et al, 2006). The importance of p130Cas tyrosine phosphorylation was fur-
ther suggested by the observation that Src, p130Cas, and Crk colocalize with one
another in the growth cone (Huang et al, 2006). NCAM and N-cadherin were found
to interact with p130Cas in the growth cone by both coimmunoprecipitation and im-
munostaining, furthermore linking p130Cas signaling to cell adhesion as both NCAM
and N- cadherin have been extensively identified as neuronal adhesion molecules (re-
viewed in Gerrow and El-Husseini (2006)).
Survival and Apoptosis
Association of p130Cas with its binding partners has been linked to survival sig-
naling whereas abrogating those interactions has been shown to induce apoptosis.
Binding of p130Cas to FAK, for instance, is associated with pro-survival signaling
in fibroblasts and cells plated on fibronectin (Almeida et al, 2000; Zouq et al, 2009).
Similarly, p130Cas has been implicated as a major mediator connecting several path-
ways through Crk to the Rac/JNK pathway (Dolfi et al, 1998), but only in the context
of integrin signaling and not in the context of EGF stimulation or v-Src expression.
However, in response to reactive oxygen species, Src appears to be essential in medi-
ating a p130Cas/Crk/JNK pathway of survival (Yoshizumi et al, 2000). Central to
all of these paradigms is the activation of the JNK pathway. Interestingly, growth
hormone (GH) stimulation of CHO cells leads to the activation of the JNK path-
way, which is concomitant with the formation of large protein complexes including
p130Cas (Zhu et al, 1998). The p130Cas protein complexes that formed in response
to GH contained not only FAK, but also CrkII, paxillin, tensin, C3G, the p85 sub-
unit of PI3-K, Grb-2, and Sos (Zhu et al, 1998). It would therefore be interesting to
dissect whether some of the proteins brought into complex with p130Cas during GH
stimulation are similarly involved in the aforementioned survival pathways.
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In the absence of serum, the binding of the p130Cas SH3 domain to the PR
regions of FAK is necessary to support survival (Almeida et al, 2000). Expression
of p130Cas constructs lacking either the SH3 or SD domains results in a dramatic
rise in apoptosis (Almeida et al, 2000). Therefore, the interaction of p130Cas with
FAK as well as p130Cas phosphorylation are important in mediating p130Cas/FAK-
mediated signaling pathways of survival (Almeida et al, 2000). Using a variety of
inhibitors, DN expression constructs, and constitutively active signaling proteins,
Almeida et al (2000) concluded that fibronectin-mediated survival signaling through
FAK/Cas results in activation of the Ras/Rac1/Pak1/MKK4/JNK pathway wherein
p-JNK is detected at FAs with FAK and is also detected in the nucleus.
The mechanisms by which FAK can promote survival in cells appears to be cell
and substrate dependent and can be linked to whether or not FAK is found in a
protein complex with p130Cas or paxillin (Zouq et al, 2009). Under conditions that
would normally promote an apoptotic state known as anoikis, wherein cells die due
to a loss of attachment to the ECM (Frisch and Ruoslahti, 1997), FAK/p130Cas
scaffolding can promote survival in fibroblasts, but not epithelial cells (Zouq et al,
2009). Expression of the SH3 domain acts as a DN in these fibroblasts, inhibiting
p130Cas phosphorylation and significantly increasing apoptosis when cells were not
allowed to attach to the substratum and serum was removed (Zouq et al, 2009).
The authors further supported the p130Cas/Crk/Rac1/Pak1/MKK4/JNK pathway
previously suggested as the mechanism leading to cell survival through FAK/p130Cas
(Almeida et al, 2000; Yoshizumi et al, 2000). Interestingly, this pathway appears to be
activated only in response to fibronectin. In the presence of collagen, FAK mediates
survival signaling independently of p130Cas (Almeida et al, 2000).
In an interesting twist, a 31-kDa fragment containing the conserved C-terminus
of p130Cas was found to localize to the nucleus where it may act as a transcriptional
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repressor of cell cycle progression (Kim et al, 2003). This fragment occurs as a re-
sult of caspase cleavage and is furthermore able to induce anoikis (Kim et al, 2003).
Kim et al (2003) suggest that, once cleaved, p130Cas may be able to further signal
in a pro-apoptotic pathway by the localization of the 31-kDa fragment to the nu-
cleus, as determined by analyzing colocalization of GFP-tagged p130Cas constructs
with Hoechst stain. A GST fusion of residues 835-908 in the p130Cas C-terminus
(those residues that would constitute the helix-loop-helix previously suggested by
Law et al (1999)) was able to pull down E47, a splice variant of E2A (Kim et al,
2003). Strangely, the authors used a longer splice variant of p130Cas for their studies
that has only been documented in rats (mouse and human p130Cas is only 874 amino
acid residues in length). The authors concluded that this 31-kDa fragment of p130Cas
dimerizes with E47, thereby allowing entry into the nucleus, and promoting apoptosis
(Kim et al, 2003). A p130Cas fragment of a similar size is seen by immunoblotting
when endothelial cell monolayers are treated with lipopolysaccharides (LPS) and sub-
sequently undergo apoptosis due to ECM detachment (Bannerman et al, 1998). This
event has also been shown to be caspase dependent and treatment of endothelial cell
monolayers with caspase inhibitors during LPS treatment prevents apoptosis (Ban-
nerman et al, 1998).
Pathogenesis
In order to mediate phagocytosis of bacteria, the cell must engage the actin cy-
toskeleton to engulf the bacteria. Some bacteria have evolved mechanisms to prevent
this uptake and ultimately their destruction. Bacteria of the genus Yersinia, such
as Y. pseudotuberculosis, employ a protein tyrosine phosphatase, which can enter
host cells and dephosphorylate its endogenous substrates (Black and Bliska, 1997).
A catalytically inactive form of such a phosphatase, YopH, has been useful to probe
for potential substrates including p130Cas (Black and Bliska, 1997). YopHC403S
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(catalytically inactive YopH) localizes to FAs in immnostaining experiments where
4G10 (pTyr antibody), paxillin, or vinculin were used as markers (Black and Bliska,
1997). While expression of WT YopH induced dephosphorylation of a band in the
130 kDa range as detected by immonoblotting for pTyr; YopHC403S transfected cells
displayed robust phosphorylation of this band (Black and Bliska, 1997). YopHC403S
transfection also led to the distribution of this phosphorylation into the insoluble
fraction (Black and Bliska, 1997). By immonoblotting experiments Black and Bliska
(1997) further demonstrated that this hyperphosphorylated protein was p130Cas (us-
ing Cas antibodies) and that YopHC403S and p130Cas bind one another (illustrated
by CoIP experiments).
Black and Bliska (1997) showed that an increased amount of p130Cas becomes
localized to FAs when YopHC403S is expressed in comparison to uninfected cells.
Note that uninfected cells did, however, exhibit some FA localization of p130Cas and
that the uninfected cells shown in the example were less well-spread than the infected
counterparts. Expression of WT YopH led to rapid dephosphorylation of p130Cas
on tyrosine residues (Black and Bliska, 1997). These data, therefore, suggest that
Yersinia can employ YopH to dephosphorylate p130Cas and that this has a nega-
tive effect on the ability of p130Cas to be targeted to FAs. Further explanation of
how targeting p130Cas for dephosphorylation benefits Yersinia was provided when
authors discovered that p130Cas/Crk signaling mediates the uptake of Yersinia by
epithelial cells (Weidow et al, 2000).
Cancer
Enhanced cell migration, invasion, cell survival, and/or proliferation have been
correlated to p130Cas expression and SD phosphorylation in a large number of cancer
types (see Tikhmyanova et al (2010) and Table. 2 for a review of p130Cas involve-
ment in various cancers). Within the context of breast cancer, however, interest in
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Table 2: Implications for p130Cas signaling in various cancer types
Cancer Type Process implicated References
Breast
Invasion (Alexander et al, 2008)
Cell proliferation and invasion (Wendt et al, 2009)
Cell proliferation
(Cabodi et al, 2004)
(Cabodi et al, 2006)
Cell survival (Soni et al, 2009)
Cell migration and invasion (Cunningham-
Edmondson and
Hanks, 2009)
Tamoxifen-resistance
(van der Flier et al,
2000)
(Brinkman et al, 2000)
(Riggins et al, 2006)
Colon
Survival
(Beinke et al, 2003)
(Casanova et al, 2006)
Proliferation (Yu et al, 2004)
Liver Invasion/poor prognosis (Guo et al, 2008)
Lung
Cell migration (Achiwa and Lazo,
2007)
Survival (Beinke et al, 2003)
Melanoma
Invasion (Nakashima et al, 2007)
Invasion and proliferation (Hamamura et al, 2005,
2008)
Multiple myeloma Cell migration (Podar et al, 2004)
Neuroblastoma Invasion (Frankel et al, 2008)
Stomach Anchorage independent growth (Noguchi et al, 2001)
p130Cas signaling and function has been the most extensive. One of the most common
and effective treatments for breast cancer is an anti-estrogen drug called tamoxifen.
However, patients can become resistant to this treatment (anti-estrogen resistant), re-
quiring a change in their treatment regimens (Dorssers et al, 2001). Using retroviral
insertion mutagenesis of a human estrogen-dependent breast cancer cell line ZR-75-1,
Brinkman et al (2000) were able to confer anti-estrogen resistance to cells and map
the integration sites of genes involved in tamoxifen resistance, including the human
homolog of p130Cas. This discovery prompted the authors to rename the p130Cas
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homolog: BCAR1 for “breast cancer anti-estrogen resistance gene 1”. Studies ad-
dressing how BCAR1/p130Cas confers antiestrogen resistance have demonstrated a
role for p130Cas in promoting cell proliferation and survival in breast cancer cells
(Cabodi et al, 2004, 2006; Riggins et al, 2006; Soni et al, 2009). As is the case with
many p130Cas signaling paradigms, SD tyrosine phosphorylation has been implicated
in these processes (Soni et al, 2009; Cunningham-Edmondson and Hanks, 2009).
Culturing cells in tamoxifen-containing media demonstrated that BCAR1 overex-
pressing cell lines had a proliferative advantage over control cells (that did not express
significant levels of BCAR1) despite the fact that ER regulated gene PS2 was similarly
affected in BCAR1 overexpressers and control cells (Brinkman et al, 2000). These
results suggest that tamoxifen resistance through BCAR1 occurs independently of
ER-regulated gene expression. Further investigation with nearly 1000 breast tumor
samples demonstrated that patients who express BCAR1 at higher levels become re-
sistant to treatment with tamoxifen and have a greater chance of disease recurrence
(van der Flier et al, 2000). Another research group showed that p130Cas is associated
with ER-α in a non-genomic manner (Cabodi et al, 2004). Instead, p130Cas appears
to associate with ER-α in a multi-molecular complex including Src and PI3-K upon
estradiol treatment (Cabodi et al, 2004). The interaction between p130Cas and ER-α
appears to be mediated by c-Src since p130Cas was not detected by CoIP with ER-α
when c-Src is first IPed from lysates and thereby excluded from the CoIP (Cabodi
et al, 2004). Kinase activity assays confirmed that overexpression of p130Cas in an
estrogen receptor-positive breast cancer cell line after estradiol treatment increases
c-Src activity, as well as ERK1/2 phosphorylation and cyclin D1 expression (Cabodi
et al, 2004). Hence, it appears that p130Cas expression in estrogen positive breast
cancer cells leads to formation of a protein complex with ER-α and c-Src to increase
Src activity resulting in ERK1/2 phosphorylation and cyclin D1 expression. Since
p130Cas overexpression is associated with tamoxifen resistance, these studies raise
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questions as to whether or not tamoxifen may also induce these protein complex
formations. This seems likely since studies have shown that tamoxifen treatment ac-
tually promotes phosphorylation of p130Cas, as well as FAK and Src (Cowell et al,
2006).
Neu/p130Cas transgenic mice display elevated activation of Src, ERK, and cy-
clin D1 in breast tissue during various stages of development and overexpression of
p130Cas in the context of Her2/Neu positive breast epithelium leads to greater tumor
burden and poorer chances of survival in those mice (Cabodi et al, 2006). Addition-
ally, p130Cas may interact with EGFR to facilitate anti-estrogen resistance through
STAT5b (Riggins et al, 2006). These results indicate the possibility of using Erb
inhibitors as adjuvant treatments for anti-estrogen resistant breast cancer treatment.
Indeed, overexpression of p130Cas may lead to other drug resistance problems as well,
as adriamycin treatment (which promotes apoptosis) is greatly hampered by p130Cas
overexpression, whereas use of single interfering RNA (siRNA) to knockdown p130Cas
expression improves the ability of adriamycin to promote apoptosis (Ta et al, 2008).
This mechanism appears to be Src, and not EGFR-dependent (Ta et al, 2008).
Independently of anti-estrogen resistance, p130Cas SD tyrosine phosphorylation
has been implicated in the promotion of cell motility and invasion (Klemke et al,
1998; Huang et al, 2002; Shin et al, 2004; Brabek et al, 2005; Rivera et al, 2006;
Cunningham-Edmondson and Hanks, 2009), while other studies have linked p130Cas
coupling to Crk in cell survival during invasion (Cho and Klemke, 2000). Conversely,
the disassociation of p130Cas and Crk in carcinoma cells, due to phosphorylation of
Crk on Y221, has been implicated in promoting apoptosis (Kain et al, 2003).
While p130Cas does not appear to promote transformation by aberrant prolifer-
ation (Brabek et al, 2004) in Src-transformed cells, p130Cas does promote formation
of invasive structures called podosomes as well as promoting proteolysis of the ECM
by metalloproteases (Brabek et al, 2005). Mutation of SD tyrosines to phenylalanines
40
reduces the ability of Src transformation to induce invasion and podosome formation
similarly to Cas -/- parental controls (Brabek et al, 2005). Mutation of the p130Cas
SH3 and SBD domains has intermediate effects on invasion and podosome formation,
whereas the SH3 mutant shows lower metalloprotease activity (Brabek et al, 2005).
A previous study had found that using a C-terminal construct of p130Cas containing
the SBD did not inhibit Src-transformation (Burnham et al, 1999). However, this
study used cells that expressed endogenous p130Cas, possibly accounting for the dis-
crepancies between the two studies.
Cell motility
p130Cas has long been associated with promotile signaling (Honda et al, 1998;
Cary et al, 1998). DOCK180/ELMO has been implicated as a major GEF involved
in Rac activation downstream of the p130Cas/Crk complex (Kiyokawa et al, 1998a,b).
Using phagocytosis to model cytoskeletal rearrangement, Reddien and Horvitz (2000)
demonstrated that Rac lies downstream of Crk and DOCK 180. Rac has further-
more been implicated in this promotile signaling by pseudopodia isolation wherein
membrane protrusions that contained higher levels of p130Cas/Crk complexes also
exhibited higher levels of Rac GTP (Cho and Klemke, 2000).
Not only do Cas -/- MEFs have a disrupted actin cytoskeleton as evidenced by
phalloidin staining, but they are also defective in their ability to promote cell motility
(Klemke et al, 1998) and adopt a well-spread morphology (Honda et al, 1999). The
inability of knock-out cells to promote efficient cell motility (Honda et al, 1999; Shin
et al, 2004) is attributed to a loss in SD phosphorylation as evidenced by the inability
of p130Cas SD point mutants to rescue motility defects (Shin et al, 2004). Similarly,
expression of a DN p130Cas whose SD has been deleted, suppresses motility in cells
expressing endogenous p130Cas (Klemke et al, 1998). The interactions between SD
pTyrs and SH2-adapter proteins Crk (Klemke et al, 1998; Chodniewicz and Klemke,
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2004; Shin et al, 2004) and Nck (Rivera et al, 2006) have been identified as critical
mechanisms driving p130Cas-mediated cell motility.
While tyrosine phosphorylation of p130Cas is necessary to enhance cell motility,
the inability to dephosphorylate p130Cas at FAs may be equally detrimental. A
role for the protein tyrosine phosphatase SHP-2 has been suggested in regulating cell
motility in response to fibronectin and vitronectin (Inagaki et al, 2000). Expression
of a catalytically inactive form of SHP-2 in Rat-1 fibroblasts leads to the formation
of larger, more stable FAs, increased cellular adhesion and cell spreading, as well as
enhanced tyrosine phosphorylation of both p130Cas and paxillin. Additionally, CHO
cells expressing a mutant SHP-2, but not the WT demonstrated reduced motility
rates after insulin stimulation (Inagaki et al, 2000).
It seems plausible that tyrosine phosphorylation of FA proteins such as p130Cas
and cell motility correlate along a bell-shaped curve where excessive phosphorylation
causes the cell to be too adherent due to the formation of prominent, stable FAs
and too little phosphorylation inhibits cell motility due to a loss of branched actin
filament assembly.
Rationale of the current study and presentation of the hypothesis
Since p130Cas appears to be phosphorylated at SD tyrosines primarily when it
is localized to FAs, the localization of p130Cas to these sites appears critical to its
ability to promote cell motility. Observation that the p130Cas CCH domain is the
most highly conserved area of the protein suggests an important role for this domain.
Further observations that this domain has some sequence similarity to the FAK FAT
domain is suggestive of this domain having an FA targeting function (Arold et al,
2002). The research in this dissertation aims to answer the following questions: 1)
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What contributions do the conserved N- and C-terminal domains make to the target-
ing of p130Cas to FAs and 2) What are the dynamics of p130Cas localization to FAs?
Additionally, preliminary data on the structural features and alternate subcellular
localizations of p130Cas will be presented.
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CHAPTER II
THE MECHANISM OF P130CAS TARGETING TO FOCAL ADHESIONS
Introduction
A full understanding of p130Cas function requires knowing the mechanism by
which it targets to FAs. Prior attempts to do so have led to contradictory conclu-
sions about the importance of the SH3, SBD, and conserved C-terminus of p130Cas
in mediating such targeting (Nakamoto et al, 1997; Harte et al, 2000). The possible
role of the C-terminal region of p130Cas as an FA targeting domain is intriguing as
there has been some speculation about the tertiary structure of this domain. Arold
et al (2002) observed that this region has some sequence similarity to the FAK FAT
domain, which folds into a bundle of four α-helices. To determine what the domain
requirements of p130Cas are to regulate its FA targeting, I used microscopy tech-
niques to visualize and quantify the FA localization of fluorophore-tagged p130Cas
variants in live and fixed cells. In addition to elucidating these aspects of p130Cas
FA targeting, the data further demonstrate that p130Cas FA localization plays an
important role in mediating integrin signaling and cell motility. The importance of
FAK in mediating the localization of p130Cas to FAs is also illustrated.
Materials and Methods
Cells and cell culture
Cas -/- MEFs were kindly provided by Hisamaru Hirai (University of Tokyo).
Paxillin -/- MEFs were a gift from Sheila Thomas (UVA School of Medicine, Char-
lottesville, VA). MEFs were grown in Dulbecco’s Modified Eagle Medium (DMEM)
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also supplemented with 10% fetal bovine serum (FBS) (Atlanta Biologicals, Lawrence-
ville, GA), 1% antibiotic/antimicotic (Mediatech, Manassas, VA), 5 µg/ml plasmocin
(InvivoGen, San Diego, CA), and 1% non-essential amino acids (Invitrogen, Carls-
bad, CA). TetFAK cells were previously described (Owen et al, 1999) and were main-
tained in the media mentioned above, which was furthermore supplemented with 5
µg of tetracycline (Calbiochem, La Jolla, CA) per ml of media to repress FAK ex-
pression. FAK expression was induced by placing cells in complete media without
tetracycline for 24 hours. Phoenix Ecotropic (E) viral packaging cells (a gift from
Gary Nolan, Stanford University) were maintained in DMEM, supplemented with
10% heat-inactivated FBS, 1% antibiotic/antimicotic, and 1% non-essential amino
acids.
Antibodies
Monoclonal mouse antibodies to total p130Cas and paxillin were obtained from
BD Transduction Laboratories (San Jose, CA). Phospho-specific pCas polyclonal an-
tibodies against p130Cas SD tyrosines 165, 249, and 410 were previously described
by Fonseca et al (2004). Mouse monoclonal antibody to β-actin was obtained from
Sigma-Aldrich (St. Louis, MO). Cy3-conjugated AffiniPure donkey anti-mouse IgG,
Texas Red dye-conugated AffiniPure donkey anti-rabbit IgG, and horseradish peroxi-
dase-conjugated goat secondary antibodies were from Jackson ImmunoResearch Lab-
oratories, Inc. (West Grove, PA).
Whole cell lysates were prepared from Cas -/- MEFs or TetFAK cells expressing
various Venus-tagged p130Cas variants by scraping on ice for 10 minutes in modified
radioimmunoprecipitation assay (RIPA) buffer (0.15 M NaCl, 50 mM Tris-HCl (pH
7.4), 1% Nonidet P40, 0.1% SDS, 1% deoxycholic acid, 5 mM EDTA, 50 mM NaF)
supplemented w/ 100 µM Na3VO4 and 1% aprotinin. Whole cell lysates were sheared
through 26 gauge needles to separate proteins from the membrane fraction.
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For pCas immunoblotting, cells were treated 6 hours with 500 µM Na3VO4 (phos-
phatase inhibitor) before lysing in modified RIPA buffer. All lysates were boiled in
2X Laemmli buffer containing 250 µM Dithiothreitol (DTT) and were separated by
7% SDS-PAGE using 20 µg protein/lane. Nitrocellulose membranes were blocked for
1 hour in Tris-buffered saline (TBS) containing 5% milk. Blots were visualized by en-
hanced chemiluminescence using Western Lightning Luminol and Oxidizing Reagent
(PerkinElmer Life Sciences, Inc., Boston, MA) using 1 minute incubations of mem-
branes prior to developing Polaroid films. Tyrosine phosphorylation of p130Cas SD
was quantified from scanned blots using ImageJ software to measure pixel intensities
to compare pCas band intensity to total p130Cas (adjusted to actin loading).
Plasmid construction and protein expression of p130Cas variants
Standard PCR-mediated mutagenesis strategies were used to create p130Cas fu-
sion proteins. pCS2-Venus-Cas-ATAA was engineered by changing the stop codon in
pCS2-Venus to ATAA by PCR amplification resulting in a shift in the open reading
frame (after the Venus-YFP coding region) so that the EcoR1 site could be used to
insert a p130Cas coding sequence that would then be expressed with an N-terminal
Venus-YFP tag. The PCR product was ligated into pGEM-T-Easy cloning vec-
tor. Positive clones were cut with BamH1/EcoR1 and the insert was placed into
BamH1/EcoR1-cut pCS2-Venus. The p130Cas sequence was then ligated into the
altered pCS2-Venus vector.
For C-terminal Venus yellow fluorescent protein (YFP) fusions, mouse p130Cas
cDNAs were generated without a STOP codon and BamH1 restriction enzyme sites
were introduced at the end of p130Cas coding regions. The WT sequence was PCR
amplified from pSK-CAS2003 with sense (5′-AGC GCG CAA TTA ACC CCA CTA
AAG-3′) and antisense (5′-GGT CCT CTG GGA TCC GGC AGC AGC-3′) oligonu-
cleotide primers. CAS∆SH3 cDNA was generated from pGEX-CAS∆SH3 using PCR
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amplification with sense (5′-AAC GCC GGA TTC GCG-3′) and antisense (5′-GGT
CCT CTG GGA TCC GGC AGC AGC-3′) oligonucleotide primers. CAS∆CCH
cDNA was generated by PCR amplification from pSK-CAS2003 using sense (5′- GCA
ATT AAC CCT CAC TAA AGG GCG AAC CGT-3′) and antisense (5′-CCG GCC
GGA TCC CAG GGG CTG GGG CTG GTG T-3′) oligonucleotide primers to ex-
clude the last 141 amino acids of p130Cas. All sequences were ligated into pGEM-
T-Easy to create pGEM-WT-CAS-gga, pGEM-CAS-∆SH3, and pGEM-CAS∆CCH,
respectively. To obtain pGEM-CAS-∆SH3/∆CCH, pGEM-CAS-∆SH3 and pGEM-
CAS∆CCH plasmids were cut with Sph1 and Sal1 restriction enzymes. The Sph1-
Sal1 fragment containing the SH3 deletion was ligated with the Sal1-Sph1 fragment
containing the CCH mutation and the pGEM backbone fragment (Sph1-Sph1) of
pGEM-CAS-∆CCH.
PGEM-CAS plasmids were digested with BamH1 and ligated into pCS2-Venus
vector (Nagai et al, 2002) using the BamH1 restriction digest sites in the vector
poly-linker region such that Venus-YFP was fused to the C-terminus of p130Cas.
To create LZRS-MS-IRES-zeo-Cas-Venus plasmids, the pCS2-Cas Venus plasmid was
cut by EcoRI restriction digestion. The p130Cas-Venus inserts were then ligated
into EcoR1-cut LZRS-MS-IRES-zeo plasmid (a gift from Al Reynolds, Vanderbilt
University), which was previously dephosphorylated by treatment with calf intestinal
phosphatase.
Stable expression of untagged p130Cas variants co-expressing green fluorescent
protein (GFP) from a separate transcript was achieved through retroviral transduc-
tion from LZRS-MS-IRES-GFP (Ireton et al, 2002) plasmids. LZRS-Cas-WT(GFP)
and LZRS-Cas-∆SH3(GFP) were previously described (Shin et al, 2004; Fonseca et al,
2004). To engineer p130Cas lacking the CCH domain with a stop codon before the
invariant proline, a T3 forward primer and the following oligonucleotide primer were
used to amplify the sequence from pSK-Cas-2003 with flanking EcoR1 sequences: 5′-
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TGA AGG CCC GAA TTC CCC TGT CCG GCC CTA CAC CAG - 3′. The same
reverse primer was used to engineer the SH3/CCH mutant cDNA, using the following
forward oligonucleotide primer to amplify the sequence from pGEX-3X-Cas-∆SH3: 5′-
AAC GCG GAT TCC CCG TCG CG -3′. These products were ligated into pGEM-
T Easy and positive clones were digested with EcoR1 for ligation into EcoR1-cut
LZRS-MS-IRES-GFP (previously dephosphorylated by calf intestinal phosphatase).
Plasmid mCherry-C1-paxilllin was generated to provide an FA marker for use in
live cell studies. The coding region of paxillin-α was subcloned into plasmid mCherry-
C1 (provided by Maria Nemethova, Vienna, Austria) from pGEX-2T-paxillin- α (pro-
vided by Hajime Yano, Osaka, Japan), such that paxillin is expressed with an N-
terminal mCherry tag. In order to do so, pGEX-2T-paxillin-α was cut with BglII
and EcoRI enzymes and the smaller fragment was ligated into mCherry-C1 vector
cut with BamH1 and EcoR1. Plasmid mCherry-C1-zyxin was a gift from Irina Kave-
rina (Vanderbilt University, Nashville, TN). All plasmid sequences were confirmed
before use.
Stable expression of p130Cas variants in Cas -/-, TetFAK, and paxillin -/- MEFs
was achieved by retroviral infection using viral supernatants of Phoenix ecotropic
(E) packaging cells transfected with LZRS-Cas-Venus plasmids or LZRS-Cas(GFP)
plasmids. Phoenix E cells were transfected by calcium phosphate transfection of 60
mm culture dishes of cells plated at ∼60% confluence. Five to ten minutes prior to
transfection, cells were treated with 25 µM chloroquine. The following transfection
mixture was made:
8 µg DNA
62 µl of 2 M CaCl2
sterile dH20 to 500 µl volume
then 500 µl 2X HBS (50 mM HEPES, 10 mM KCl, 12 mM dextrose, 280 mM NaCl,
1.5 mM Na2PO4, pH 7.7)
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The mixture was pipetted vigorously to produce bubbles for 15 seconds and then
applied to the dish containing the chloroquine-treated Phoenix E cells. Transfection
proceeded for 7 hours at 37◦C after which the media was replaced and cells were
allowed to recover for 48 hours .
Forty-eight hours after transfection, Phoenix E cells were shifted to the permissive
temperature (33◦C) to produce virus. After overnight incubation, viral supernatants
were taken from the cells, which were subsequently spun down and filtered through a
0.45 µm syringe filter. Phoenix E cells were shifted back to 37◦C and then subjected
to puromycin selection with 5 µg puromycin per ml of media (2 weeks after selection,
more viral supernatants were obtained). Before viral supernatants were added to Cas
-/- MEFs, polybrene was added to the filtered supernatants at a concentration of 4
µg/ml. Once viral supernatants were added to cells, they were shifted to 33◦C for 6
hours to promote infection. Three rounds of infection with the viral supernatants were
performed. For p130Cas(∆SH3) tagged and untagged variants, it was necessary to
select three clones of higher expressers to produce a clonal population that expressed
at levels equivalent to sorted cell populations (prior attempts at achieving equivalent
expression using cell sorting failed due to a rapid loss of expression). Paxillin -/- cells
expressing p130CasVenus(WT) were analyzed after infection prior to sorting. All
other p130CasVenus and untagged p130Cas cell populations were further selected by
fluorescence activated cell sorting (FACS) for YFP and GFP, respectively, to obtain
a population in the lower half of the fluorescence ranges.
After infection and sorting for low levels of Venus-YFP, cells were periodically
maintained in media containing 10 µg/ml zeocin (Invitrogen) to assure continued ex-
pression from the bicistronic transcript that includes the bleomycin resistance gene
expressed from the internal ribosome entry site. Transient expression of mCherry-
paxillin and mCherry-zyxin was achieved by transfection with Lipofectamine LTX
according to manufacturer’s instructions (Invitrogen, Carlsbad, CA) using 12 µl of
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reagent to 3 µg of DNA in OptiMEM media (Invitrogen, Carlsbad, CA). Cells were
incubated for 16 hours in transfection media after which cells were placed in normal
DMEM supplemented as indicated above in “Cells and Cell Culture”. For Venus-
p130Cas(WT), Lipofectamine 2000 reagent was used instead and the incubation time
was lessened to 7 hours.
Wide-field fluorescence microscopy
Cas -/- MEFs transiently transfected with pCS2-Venus-Cas-ATAA were plated
on glass coverslips coated with 10 µg/ml fibronectin. Live cells were mounted for
microscopy using PBS as an interface between coverslips and glass slides. To reveal
p130Cas tyrosine phosphorylation by immunostaining experiments, cells were grown
on glass coverslips coated with 10 µg/ml fibronectin and fixed in 2% paraformaldehyde
dissolved in a buffer containing 20 mM PIPES (pH 7.1), 127mM NaCl, 5mM KCl,
1.1mM NaH2PO4, 0.4 mM KH2PO4, 2mM MgCl2, 5.5 mM glucose, and 1mM EGTA.
Cells were permeabilized for 10 minutes in 0.4% Triton-X in phosphate buffered saline
(PBS). After blocking for 1 hour with 1% bovine serum albumin (BSA) in PBS,
the coverslips were placed in a primary antibody solution with phosphoCas-Y165
antibody with detection by Texas Red dye-conjugated secondary antibody. Coverslips
were kept in the dark once secondary antibody was added to prevent fluorophore
degradation. The coverslips were mounted in Vectashield Mounting Media (Vector
Labs, Burlingame, CA).
Images of live fluorescent cells were captured by QED Capture software (Media
Cybernetics, Silver Spring, MD) through a 60X/1.40 oil immersion lens, whereas as
immunostained cells were imaged a through a 100X/1.40 oil immersion lens on an
upright Nikon Eclipse 80i microscope (Nikon, Melville, NY) equipped with Nikon
Epifluorescence D-FL attachments. Fluorophores were excited by an EXFO X-Cite
50
120 fluorescence illumination system (EXFO, Quebec, Canada) using Nikon C-FL G-
23/C TRITC and C-FL B-2E/C FITC filter cubes. After capture, TIFF images were
imported into Adobe Photoshop CS (Adobe, San Jose, CA) and the autocontrast
function was used to adjust the images.
TIRF imaging of FAs in live cells
Cas -/- MEFs expressing p130CasVenus variants were transiently transfected with
plasmid mCherry-C1-paxillin, and then grown to confluence on coverslips coated with
1 µg/ml fibronectin (from human plasma, Sigma-Aldrich, St. Louis, MO). Two hours
prior to analysis, scratch wounds were prepared by creating denuded areas using
a pipette tip. Media was aspirated from these cells to remove cellular debris and
fresh media was applied, which was furthermore supplemented with 10mM HEPES
to maintain media pH when cells were placed outside of the incubator on the micro-
scope stage. Shortly before microscopy analysis, wounded coverslips were mounted
into a chamber containing this same media, which was furthermore covered with a
clean coverslip to prevent debris from entering the chamber. The temperature of
this chamber was maintained by a heater (at 37◦C). Cells migrating into the wound
and expressing both fluorophores to appropriate levels were chosen for analysis of dy-
namic FAs using total internal reflection fluorescence (TIRF) microscopy, which was
performed on a Nikon ECLIPSE TE2000-E inverted microscope equipped with a Per-
fect Focus System and a TIRF 100X/1.49 NA oil-immersion lens. Fluorophores were
excited with an 18 mW argon laser (Melles Griot) and 10 mW DPSS laser 85YCA010
(Melles Griot, Albuquerque, NM). A custom-made double-dichroic TIRF mirror and
emission filters (Chroma Technology, Rockingham, VT) in a Ludl filter wheel (Ludl,
Hawthorne, NY) were used to make two-color movies at 25 second intervals between
frames for a total of 180 frames.
Images were captured by a back-illuminated EM-CCD camera Cascade 512B
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(Photometrics) driven by IPLab (Scanalytics, Fairfax, VA) software. Images were
imported into ImageJ (NIH – open source software), where file type was converted
to 8-bit grayscale. Background (non-cellular) was zeroed on each image by adjusting
the lower limit of the display range using the brightness/contrast function in ImageJ.
Analysis of p130Cas localization to FAs in fixed cells
Cells expressing p130CasVenus variants were fixed, immunostained for paxillin
as an FA marker, and visualized by confocal spinning disk fluorescence microscopy.
Cells growing at low density on coverslips coated with 10 µg/ml fibronectin (from
human plasma, Sigma-Aldrich, St. Louis, MO) were fixed for 30 minutes in 2%
paraformaldehyde (in a buffer containing 20 mM PIPES (pH 7.1), 127mM NaCl,
5mM KCl, 1.1mM NaH2PO4, 0.4 mM KH2PO4, 2mM MgCl2, 5.5 mM glucose, and
1mM EGTA), and then permeabilized for 10 minutes in 0.5% Triton-X in PBS. After
blocking for 1 hour with 1% BSA in PBS, the coverslips were immunostained for
paxillin with detection by Cy3-conjugated secondary antibody. Coverslips were kept
in the dark once secondary antibody was added to prevent fluorophore degradation.
The coverslips were mounted in Prolong Gold Mounting Media (Invitrogen).
Confocal images were captured at a single 0.2 µm slice depth (at the most appro-
priate ventral plane for visualizing FAs) with a Yokogawa QLC-100/CSU-10 spinning
disk head attached to a Nikon TE2000E microscope using a 100X/1.4 oil Plan Apo
objective lens (Nikon), and a back-illuminated EM-CCD camera Cascade 512B driven
by IPLab software. Two-color excitation was achieved by a krypton-argon laser (75
mW 488/568 from Melles Griot with AOTF control). Custom-made double dichroic
mirror and filters (Chroma Technology) were used in a Ludl filter wheel. Images were
processed to remove non-cellular background as described above. These slices were
then inverted in order to locate areas of robust paxillin staining for analysis. From
these robust areas of staining, 50 FAs (10 each from 5 separate cells) were selected
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for each experimental population. Masks of the selected FA sites were created based
on paxillin-delimited boundaries. The masks were then superimposed onto the corre-
sponding images in the green emission channel to obtain measurements of the mean
Venus-YFP fluorescence within the FAs. Non-FA-associated Venus-YFP fluorescence
was subtracted from these values, based on measurements of single, adjacent cellu-
lar areas using the same FA masks. Calculations were performed in Microsoft Excel
and statistical significance was analyzed using Excel T-Test function to perform an
unpaired, two-tailed, Student’s t-test.
Cell motility assay
Scratch wounds were created, as described above, in confluent cell monolayers
on coverslips coated with 1 µg/ml fibronectin and analyzed by differential inter-
ference contrast (DIC) microscopy. The wounded monolayers were then placed in
complete DMEM further supplemented with 10 mM HEPES, mounted into a 37◦C
heating chamber on an inverted Nikon ECLIPSE TE2000-E2 microscope, and visu-
alized through a 20X Plan Apo DIC objective lens. Frames were captured every 5
minutes for 8 hours on a CoolSnapHQ camera (Photometrics) using IPLab software.
Sixty representative cells at wound margins (12 each from 5 independent wounds per
experimental population) were followed using the ImageJ manual tracking function.
The mean total distances traveled per hour were calculated, starting at 2 hours after
wounding. The average total distance traveled per hour was calculated after 5 and
8 hours migration after wounding (meaning that each movement was tracked from
frame to frame and summed, then divided by the total number of hours migrated
from hour 2). Statistical significance was determined using an unpaired, two-tailed,
Student’s t-test.
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Results
Development and characterization of fluorophore-tagged p130Cas
In order to study p130Cas localization in live and fixed cells, it was desirable
to create a fluorescent fusion protein with good photo- and thermo-stable properties.
Since the discovery of green fluorescent protein (GFP), many fluorescent proteins have
been discovered and the properties of GFP have also been altered by mutagenesis
strategies to alter the properties of the protein. Due to such advances, a yellow
fluorescent protein (YFP) called Venus, with superior properties for live cell imaging
was identified (Nagai et al, 2002). Initial experiments with an N-terminal Venus-
YFP fusion of the WT p130Cas protein, Venus-p130Cas(WT), resulted in an aberrant
localization of p130Cas wherein the protein was primarily localized to the nucleus and
appeared to be excluded from FAs (Fig. 5). For this reason, the N-terminal fusion
protein was found unsuitable for further analysis.
Figure 5: Fusing Venus-YFP to the N-terminus of p130Cas results in an aberrant
subcellular localization. A plasmid expressing p130Cas with an N-terminal Venus-
YFP tag was transiently transfected into Cas -/- MEFs. Live cells plated on the
coverslip were gently pressed against a glass slide in the presence of PBS. Microscopy
was performed using a 60X lens on a wide-field fluorescence microscope. Scale bar is
10 µm.
Placing the Venus-YFP tag on the C-terminal end of the protein eliminated the
aberrant localization to the nucleus. By wide-field fluorescence microscopy, p130Cas-
Venus(WT) could be seen localizing to structures that appeared to be FAs and in
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a large cytoplasmic pool (see Fig. 6), consistent with previous studies of p130Cas
localization (Nakamoto et al, 1997; Harte et al, 2000; Fonseca et al, 2004; Ballestrem
et al, 2006).
Figure 6: Using a C-terminal Venus-YFP tag results in normal subcellular localiza-
tion of p130Cas. Cas -/- MEFs expressing p130Cas fused to a C-terminal Venus-YFP
tag were plated on fibronectin-coated coverslips and visualized by live wide-field fluo-
rescence microscopy using a 100X objective lens. Areas with FA-like appearance are
indicated with arrows. Scale bar is 10 µm.
Further studies with p130CasVenus(WT), wherein mCherry-paxillin was used as
a marker of FAs, illustrated that the protein localized to FXs (Fig. 7) as well as larger
FAs at the leading and trailing edge of cells. In order to visualize these structures,
I employed total internal reflection fluorescence (TIRF) microscopy, since the large
cytoplasmic pool of p130Cas often obscured such sites in as is seen by wide-field flu-
orescence imaging.
Expression of p130Cas variants tagged with fluorophore Venus-YFP
To study the mechanism p130Cas localization to FAs, mouse p130Cas variants
tagged at their C-terminal ends with the fluorophore Venus-YFP were stably ex-
pressed to similar levels in Cas -/- mouse embryo fibroblasts (MEFs) using a retro-
viral vector. Cells were sorted for low levels of YFP expression using fluorescence
activated cell sorting (FACS). C-terminally tagged p130Cas variants included WT,
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Figure 7: p130CasVenus(WT) localizes to FXs. Cas -/- MEFs expressing
p130CasVenus(WT) plated on fibronectin-coated coverslips were transiently trans-
fected with mCherry-paxillin to mark FAs and FXs and were then visualized by live
TIRF microscopy. Arrows indicate FXs. Scale bar is 10 µm.
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∆SH3, ∆CCH, ∆SH3/∆CCH, and CCH only (Fig. 8).
Figure 8: p130Cas deletion mutants. Indicated are positions of the N-terminal SH3
domain, the substrate domain (SD), the Src-binding domain (SBD), and the Cas-
family C-terminal homology (CCH) domain. To study subcellular localization, the
variants were expressed with Venus-YFP fused to their C-termini.
Based on sequence conservation among members of the Cas family, including a
distant relative from Drosophila, the Cas-family C-terminal Homology (CCH) domain
was defined as the 141 amino acid residues at the C-terminus, beginning with an
invariant proline (Fig. 9).
Within the p130Cas CCH domain are three 25-30 amino acid stretches strongly
predicted to adopt alpha-helical secondary structure (Fig. 9). While these predicted
helical regions correspond to three of the four helices of the FAK FAT domain, β-
strand content is predicted for a highly conserved stretch in the p130Cas CCH domain
that would correspond to the other FAK FAT helix (Fig. 9).
Immunoblotting of total cell lysates confirmed that p130CasVenus variants are
expressed to roughly equivalent levels and have the expected SDS-PAGE mobilities
(Fig. 10, top panel).
The signaling capacities of the variants was assessed by immunoblotting with
a mixture of three pCas phospho-specific antibodies that recognize phosphorylated
YxxP tyrosines in the p130Cas SD (Fonseca et al, 2004). To better enable detection
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Figure 9: Cas-family C-terminal homology domains. Shown in the amino acid
sequence alignment are mouse p130Cas residues 734-874 (UniProt ID Q61140),
mouse “Human Enhancer of Filamentation 1” residues 693-833 (mHEF1, UniProt
ID O35177), mouse “Embryonal Fyn-associated substrate” residues 421-560 (EFS,
UniProt ID Q64355), Drosophila melanogaster p130Cas homolog residues 683-823
(DmCas, UniProt ID A4IJ58), and mouse “HEF1-EFS-p130Cas-like” residues 672-
804 (HEPL, UniProt ID Q08EC4). C-termini are indicated by asterisks. Positions
of amino acid identity have a black background, while other well-conserved positions
have a grey background. A secondary structure prediction for the p130Cas CCH
domain, made using Jpred 3 (Cole et al, 2008), is shown at the top of the alignment,
with α-helices indicated by HHH and β-strands by EEE. The numbers ranging from 0
to 9 indicate prediction reliability, with larger numbers indicating greater reliability.
Figure 10: Venus-YFP tagged p130Cas variants lacking either the SH3 or
CCH domain are deficient in SD phosphorylation. Immunoblot (IB) analy-
sis was carried out on whole cell lysates from Cas -/- MEFs reconstituted
with either p130CasVenus(WT), p130CasVenus(∆SH3), p130CasVenus(∆CCH), or
p130CasVenus(∆SH3/∆CCH). Parental Cas -/- MEFs and normal Cas +/+ MEFs
were included as controls. Blotting with an antibody for total p130Cas indicated that
the variants were expressed to equivalent levels (top). SD tyrosine phosphorylation
was assessed, from vanadate-treated cells, using a mixture of pCas phospho-specific
antibodies that recognize SD YxxP sites (middle). Actin was detected as a loading
control (bottom).
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of SD phosphotyrosines, cells were pretreated with Na3VO4 to inhibit tyrosine phos-
phatases. p130CasVenus(WT) achieved a level of SD tyrosine phosphorylation close
to that of endogenous p130Cas (Fig. 10, middle panel).
However, deletion of either the SH3 or CCH domain significantly impaired SD
tyrosine phosphorylation such that only faint pCas immunoreactivity could be de-
tected, and only upon prolonged exposure of the blot (Fig. 10, middle panel). Thus
both the SH3 and CCH domains are required for proper p130Cas signaling. By pCas
Y165 (phospho-specific antibody to p130Cas tyrosine 165) immunostaining, phos-
phorylation of these p130Cas variants was readily seen at FA sites (Fig. 11). As was
seen by immunoblotting of whole cell lysates, p130CasVenus(WT) appeared to be
robustly phosphorylated at FAs, whereas the SH3 and CCH mutants exhibited less
phosphorylation, with the SH3 mutant showing the greatest reduction in phosphory-
lation (Fig. 11). P130CasVenus targeting to FAs appeared to be reduced in mutants
experiencing losses in tyrosine phosphorylation.
Both the SH3 and CCH domains are important for targeting p130Cas to FAs
The localization of p130CasVenus mutants was analyzed in live cells using paxillin
as a control FA marker. Cells were transiently transfected to express paxillin tagged
with the mCherry fluorophore. Paxillin is an established marker of FAs throughout
their lifetime (Zaidel-Bar et al, 2003; Webb et al, 2004) and was therefore a desirable
standard to which p130Cas could be compared. By total internal reflection fluores-
cence (TIRF) microscopy, p130CasVenus(WT) is observed to localize quite distinctly
to FAs, with little Venus-YFP signal seen in adjacent ventral areas (Fig. 12). How-
ever, neither p130CasVenus(∆CCH) nor p130CasVenus(∆SH3) was able to achieve
the same discrete FA localization. Rather, both of these deletion mutants became
more broadly distributed in the ventral region of cells, with only modest enrichment
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Figure 11: Tyrosine phosphorylation of p130Cas occurs at FAs and is reduced
in SH3 and CCH mutants. The colocalization of p130CasVenus variants and
p130Cas tyrosine phosphorylation was assessed by wide-field fluorescence microscopy.
Immunostaining with a phospho-specific antibody to p130Cas Y165 served to
mark tyrosine phosphorylated p130Cas. Representative images of cells expressing
p130CasVenus(WT), (∆SH3), and (∆CCH) are shown. In the merged images, the
green channel represents p130CasVenus (left panels), red identifies phospho-Cas stain-
ing with pY165 antibody (center panels), and yellow indicates areas of colocalization
(right panels). Scale bar is 10 µm.
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in and around the vicinity of FAs (Fig. 12 B-C). The CCH domain alone also exhib-
ited this limited capacity for FA targeting, similarly to the ∆CCH and ∆SH3 variants
(Fig. 12 D). The double mutant was excluded from these studies as cells expressing
p130CasVenus(∆SH3/∆CCH) were difficult to distinguish by TIRF (since most of
the fluorophore appeared in the cytoplasm and not in the ventral FA regions).
To further assess the mechanism of p130Cas targeting to FAs, the Venus-tagged
variants, including the ∆SH3/∆CCH mutant, were visualized at the ventral region
of fixed cells using confocal microscopy. Paxillin immunostaining served to mark
the FAs. By this method, the prominent FA localization of p130CasVenus(WT) was
again evident, although cytoplasmic localization is more apparent than with TIRF mi-
croscopy (Fig. 13, top panels). The much weaker FA targeting of p130CasVenus(∆SH3)
and p130CasVenus(∆CCH) was also apparent (Fig. 13, middle panels). For p130Cas-
Venus(∆SH3/∆CCH), however, there was no FA localization (Fig. 13, bottom pan-
els).
To quantify the FA targeting efficiencies of the variants, mean Venus fluorescence
values were determined from measurements of 50 FAs, within the boundaries set
by paxillin staining. Relative to p130CasVenus(WT), the FA targeting efficiency of
p130CasVenus(∆CCH) was reduced by∼3-fold and∼6-fold for p130CasVenus(∆SH3)
— see Fig. 14.
The difference in FA targeting between p130CasVenus(∆CCH) and p130Cas(∆SH3)
was significant. The FA localization of p130CasVenus(∆SH3/∆CCH) was below the
background level of fluorescence in adjacent areas (Fig. 14). Thus, it is clear that both
the SH3 and CCH domains make important contributions to the proper FA targeting
of p130Cas, and that no FA targeting is achieved in the absence of both domains.
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Figure 12: p130Cas mutants lack discrete localization to FAs. Live TIRF microscopy
was used to assess the localization of p130CasVenus variants (WT, ∆CCH, ∆SH3,
or CCH only) within the ventral plane of cells migrating from the edge of a wounded
cell monolayer. To mark adhesion sites, cells were transfected to transiently express
mCherry-paxillin. The larger panels show merged images of representative single cells
at the wound margin, with arrows indicating direction of migration. Boxed areas en-
closing well-defined FAs are shown slightly enlarged in adjacent panels that separately
show the Venus, mCherry, and merged fluorescence. Note that both ∆CCH and ∆SH3
variants lack the discrete FA localization that is apparent for p130CasVenus(WT).
Also note that the CCH only variant localizes poorly to FAs. Scale bar is 5 µm.
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Figure 13: Both the CCH and SH3 domains play important roles in targeting p130Cas
to FAs. The localization of p130CasVenus variants to FAs was assessed by fluorescence
confocal microscopy at a single ventral slice. Immunostaining for endogenous paxillin
served to mark FAs. Representative images of cells expressing the p130CasVenus
variants: WT, ∆CCH, ∆SH3, or ∆SH3/∆CCH. P130CasVenus fluorescence is shown
as green (left panels), paxillin immunofluorescence as red (center panels), and colo-
calization as yellow in the merged images (right panels). Insets represent 2-fold en-
largements of selected areas containing FAs. Scale bar is 10 µm.
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Figure 14: Deletion of either targeting domain significantly decreases p130Cas lo-
calization to FAs. Quantitative analysis of mean p130CasVenus fluorescence at FAs.
Paxillin immunofluorescence was used to delineate FA borders, and mean Venus-YFP
fluorescence values were measured from within the FA boundary. For each p130Cas
variant, mean Venus-YFP fluorescence was determined from 50 FAs (10 each from 5
separate cells). Bars indicate SEM. Statistical significance was determined by Stu-
dent’s t-test.
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FAK Has a Role in the FA Targeting of p130Cas
The finding that the SH3 domain is required for the proper targeting p130Cas to
FAs suggests that the interaction of this domain with FAK may be involved in the pro-
cess. To evaluate the role of FAK in targeting p130Cas to FAs, p130CasVenus(WT)
and p130Cas(∆CCH) were stably expressed in TetFAK cells, which are FAK -/- MEFs
engineered for inducible FAK expression upon tetracycline withdrawal (Owen et al,
1999). The equivalent expression of the p130CasVenus variants in the TetFAK cells
was confirmed by immunoblot analysis, under both non-induced and FAK-induced
conditions (Fig. 15).
.
Figure 15: Expression of FAK and p130CasVenus in TetFAK cells. Immunoblot
analysis of whole cell lysates from TetFAK parental cells and cells expressing either
p130CasVenus(WT) or p130CasVenus(∆CCH) that were either induced to express
FAK or kept in the non-induced condition. Detection with a total p130Cas anti-
body (top) shows the expression of the two p130CasVenus variants in comparison
to endogenous p130Cas. A total FAK antibody was used to confirm induced FAK
expression (middle), while actin detection was used as a loading control (bottom)
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The FA targeting efficiencies of the two p130CasVenus variants, both in the pres-
ence and absence of FAK, were quantified as described above from peripheral FAs
at the leading edge of cells. FAK expression significantly increased FA targeting effi-
ciency of both p130CasVenus(WT) and p130CasVenus(∆CCH) (Fig. 16 and Fig. 17).
For p130CasVenus(WT), the increase was ∼3-fold. Even in the presence of FAK,
p130CasVenus(∆CCH) localized very poorly to FAs and was ∼10-fold reduced in
comparison to p130CasVenus(WT). In the absence of FAK, the weak FA targeting of
p130CasVenus(∆CCH) was no longer apparent. Thus, FAK has an important role in
the FA targeting of p130Cas and without FAK, the FA targeting function achieved
by the p130Cas SH3 domain is lost.
Both the SH3 and CCH domains are required for efficient promotion of cell motility
by p130Cas.
Results presented above document the importance of the SH3 and CCH domains
in p130Cas FA targeting and signaling. To extend these observations, we investigated
the requirements for the SH3 and CCH domains in the ability of p130Cas to promote
cell motility. For this investigation, p130Cas variants without the Venus tag were sta-
bly expressed in Cas -/- MEFs. By using a retroviral vector that co-expresses GFP
from a bicistronic transcript, cell populations were sorted for low GFP expressers
and populations were obtained that express p130Cas variants at levels comparable
to the endogenous protein (Fig. 18, top panel). Vanadate treatment followed by
immunoblotting with pCas antibodies revealed that the extent of SD tyrosine phos-
phorylation was reduced in all of the deletion mutants in comparison to WT (Fig. 18,
middle panel).
SD tyrosine phosphorylation was barely detectible in the ∆SH3 and ∆SH3/∆CCH
mutants, while quantitative analysis indicated that SD tyrosine phosphorylation of the
∆CCH mutant was reduced by 50% in comparison to p130Cas(WT). The impairment
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Figure 16: Confocal Images of TetFAK cells expressing p130CasVenus mutants. The
localization of p130CasVenus variants to FAs was assessed by fluorescence confocal
microscopy at a single ventral slice. Immunostaining for endogenous paxillin served
to mark FAs. Representative images of cells expressing p130CasVenus(WT) and
(∆CCH) are shown in the presence (+) or absence(-) of FAK. p130CasVenus fluo-
rescence is shown as green (left panels), paxillin immunofluorescence as red (center
panels), and colocalization as yellow in the merged images (right panels). Insets
represent 2-fold enlargements of selected areas containing FAs. Scale bar is 10 µm.
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Figure 17: FAK mediates the localization of p130Cas to FAs through the SH3 do-
main. Quantitative analysis of mean p130CasVenus fluorescence at FAs. Paxillin
immunofluorescence was used to delineate FA borders, and mean Venus-YFP fluores-
cence values were measured from within the FA boundary. For each p130Cas variant,
mean Venus-YFP fluorescence was determined from 50 FAs (10 each from 5 separate
cells). Bars indicate SEM. Statistical significance was determined by Student’s t-test.
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Figure 18: Both the SH3 and CCH domains are required for p130Cas sig-
naling. Immunoblot analysis of whole cell lysates from Cas -/- MEFs re-
constituted with untagged p130Cas(WT), p130Cas(∆SH3), p130Cas(∆CCH), or
p130Cas(∆SH3/∆CCH). Parental Cas -/- MEFs and Cas +/+ MEFs were included
as controls. Expression of the p130Cas variants was demonstrated using an antibody
that recognizes both phosphorylated and unphosphorylated protein (top), while SD
tyrosine phosphorylation was assessed using a mixture of pCas antibodies (middle).
Prior to lysis, cells were treated with vanadate to enhance detection of SD phospho-
rylation. Actin was detected as a loading control (bottom).
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of SD tyrosine phosphorylation observed for the ∆CCH mutant is not as striking as
the defect observed for p130CasVenus(∆CCH), indicating that the Venus-YFP tag
has a limited negative effect on this signaling function. Nevertheless, it remains
evident that the CCH domain has an important role in p130Cas SD signaling.
To study cell motility, scratch wounds were made in confluent cell monolayers
and live, differential interference contrast (DIC) microscopy was used to monitor
the movement of cells into wounds for determination of mean cell migration rates.
Consistent with results from other studies (Huang et al, 2002; Shin et al, 2004),
p130Cas(WT) expression significantly increased the cell migration rate as compared
to parental Cas -/- cells (Fig. 19). Notably, the abilities of the deletion mutants to
promote migration correlated with their extent of tyrosine phosphorylation. Thus,
neither the ∆SH3 nor the ∆SH3/∆CCH mutants promoted migration above the level
observed for Cas -/- cells, while the ∆CCH mutant was not able to promote migration
above the level of Cas -/- MEFs initially (at 5 hours), but eventually recovered the
ability to migrate at an intermediate level to Cas -/- MEFs and p130Cas(WT) MEFs
(Fig. 19).
As evident in the representative wounds shown in Fig. 20, many p130Cas(WT)
cells are well separated from the margin at the 5 hour time point, whereas Cas -/- cells
and cells expressing the signaling-deficient p130Cas mutants still maintain a uniform
edge. Thus, in addition to promoting p130Cas FA targeting, both the SH3 and CCH
domains are important for achieving proper SD tyrosine phosphorylation in order to
promote cell motility.
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Figure 19: Deletion of either the SH3 or CCH domain significantly reduces cell motil-
ity. Scratch wounds made in confluent cell monolayers were monitored by live DIC
microscopy. For quantitative analysis, 60 individual cells (12 cells per 5 separate
wounds) were tracked from each cell population, and mean migration rates were de-
termined from the total distances migrated over a 5- (A) and 8-hour period (B). Bars
indicate SEM, and significance was determined by Student’s t-test.
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Figure 20: Both the SH3 and CCH domains are required for p130Cas to promote cell motility. Scratch wounds made in confluent
cell monolayers were monitored by live DIC microscopy. Representative images of wound margins taken at 2, 5, and 8 hours
post-wounding are shown. Scale bar is 50 µm.
73
Discussion
In this chapter, the FA localization of Venus-tagged p130Cas variants was studied
in live and fixed cells in order to clarify the FA targeting mechanism of p130Cas. Two
past studies addressed this question using immunostaining to detect epitope-tagged
p130Cas variants (Nakamoto et al, 1997; Harte et al, 2000). Both studies found that
deletion of the SD had no effect on FA targeting, indicating that SD tyrosine phos-
phorylation was not involved. However, the two studies reached fundamentally differ-
ent conclusions as to which domains were required for the FA targeting of p130Cas.
Nakamoto et al (1997) found that the SH3 domain was essential for p130Cas targeting
to FAs. In contrast, Harte et al (2000) reported no inhibitory effect on FA localiza-
tion when the SH3 domain was functionally impaired by mutation in the context
of the full-length protein. Both studies supported the existence of an FA targeting
sequence lying at or near the p130Cas C-terminus, but disagreed as to which domain
is involved. Nakamoto et al (1997) concluded that the SBD is required for efficient
FA targeting based on studies of a deletion mutant lacking this domain. However,
Harte et al (2000) saw no effect on the FA targeting of a p130Cas variant with SBD
mutations and instead reported that the C-terminal 182 amino acid residues con-
tained a region essential for FA targeting. Neither of these previous studies included
quantitative analyses to evaluate the p130Cas FA targeting mechanism, which may
have contributed to the different conclusions reached.
Use of Venus-tagged p130Cas variants in these studies has allowed me to clarify
the domain requirements for FA targeting of p130Cas. In contrast to the conclusions
reached by either Nakamoto et al (1997) or Harte et al (2000), it is now clear that
both the N-terminal SH3 and C-terminal CCH domains are necessary for p130Cas to
properly localize to FAs. Quantitative analysis of fixed cells showed that deletion of
either the SH3 or CCH domain leads to a significant impairment in the FA localization
of p130CasVenus, while complete loss of FA targeting occurs only when both domains
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are deleted. Live cell TIRF imaging of the SH3 or CCH domain deletion mutants
provided further evidence of their targeting defects. Even when these mutants are
detected at FAs, it is apparent that this is an abnormally indiscrete association. Our
identification of a C-terminal FA targeting sequence is consistent with the findings
of Harte et al., while further defining this region to include just the CCH domain.
While the main conclusion of Harte et al. was that the C-terminal region is sufficient
to target p130Cas to FAs, they did recognize that the SH3 domain has the capacity
for FA targeting and must be functionally impaired in the context of their C-terminal
deletion mutant before FA localization was fully lost. The findings presented in this
chapter, however, emphasize that the CCH domain is unable to properly localize
p130Cas to FAs in the absence of the SH3 domain.
Note that the SBD deletion mutant used in the Nakamoto et al (1997) study
was derived by excision of a large Hind III fragment (Nakamoto et al, 1995) that
encodes not only the SBD but also a significant portion of the CCH domain. Thus
the observed deficiency in the FA targeting of this mutant is likely due to the partial
loss of the CCH domain, rather than loss of SBD function.
As noted in Chapter 1, FAK is a prominent FA protein that interacts with the
p130Cas SH3 domain (Polte and Hanks, 1995; Harte et al, 1996; Polte and Hanks,
1997). Results obtained in this study using an inducible FAK expression system
provide the first solid evidence that the FAK interaction is the main mechanism by
which the p130Cas SH3 domain targets to FAs. Thus FAK serves the dual functions
of recruiting p130Cas to FAs and recruiting Src to phosphorylate the p130Cas SD in
order to promote downstream signaling.
As discussed in Chapter 1, it has been speculated that the CCH domain may adopt
a fold similar to the FAK FAT domain, a four-helix bundle stabilized by a hydrophobic
core (Arold et al, 2002; Hayashi et al, 2002; Liu et al, 2002). The results presented
here lend support to the possibility that the CCH domain may have a similar tertiary
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structure to the FAK FAT domain by demonstrating that the p130Cas CCH domain
does, indeed, have the ability to function as an FA targeting domain. However, our
results emphasize that the CCH domain by itself is a rather inefficient FA targeting
domain. Unlike the FAK FAT domain, only three helices are strongly predicted to lie
within the CCH domain. Until the CCH domain tertiary structure is determined, it
will remain a matter of speculation as to whether or not the CCH domain actually
adopts a four-helical bundle structure.
The nature of the target protein(s) for the p130Cas CCH domain in promoting FA
localization is also uncertain. One possibility is paxillin, which plays a major role in
targeting by the FAK FAT domain (Tachibana et al, 1995), with paxillin LD motifs
binding to opposite faces of the four-helix bundle (Bertolucci et al, 2005). However,
in preliminary studies using mCherry-zyxin as an FA marker, no deficiency in the FA
targeting of p130CasVenus(WT) was observed in paxillin -/- MEFs (Fig. 21).
Two proteins known to interact with the C-terminal region of p130Cas are AND-
34/BCAR3 (Riggins et al, 2003) and Ajuba (Pratt et al, 2005). However, neither
protein is a strong candidate as the CCH domain target in localizing p130Cas to
FAs. AND-34/BCAR3 is not a prominent FA protein, and was actually implicated in
recruiting p130Cas away from FAs to the general cell periphery (Riggins et al, 2003).
From studies of Ajuba -/- cells, it is also evident that Ajuba is not required for p130Cas
localization to FAs and Ajuba has no effect on p130Cas tyrosine phosphorylation
(Pratt et al, 2005). Thus additional studies are needed to identify the CCH domain-
interacting protein(s) responsible for the recruitment of p130Cas to FAs.
Finally, the findings presented in this chapter are highly relevant to the proposed
role for p130Cas signaling in cell motility and mechanotransduction. Consistent with
a role for the CCH domain in FA targeting, we further showed that the CCH domain
is required for maximal SD tyrosine phosphorylation and promotion of cell motility
by p130Cas. Tyrosine phosphorylation of the p130Cas SD has been strongly linked
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Figure 21: The localization of p130CasVenus(WT) to FAs is not lost in paxillin -/-
MEFs. A. Two representative paxillin -/- MEFs stably expressing p130Cas(Venus)
and transiently expressing mCherry-zyxin are shown. P130CasVenus(WT) is in green,
mCherry-zyxin in red, and colocalization is indicated by yellow. Images were taken
through a 100X objective lens by TIRF microscopy. Scale bar is 10 µm. B. Whole
cell lysates from Cas -/- MEFs or paxillin -/- MEFs expressing p130CasVenus(WT)
were subjected to immunoblotting to detect paxillin expression. Actin is shown as a
loading control.
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to its ability to promote cell motility, with subsequent recruitment of Crk and/or Nck
adaptors acting to promote actin dynamics and plasma membrane protrusion (Klemke
et al, 1998; Cho and Klemke, 2000; Huang et al, 2002; Shin et al, 2004; Brabek et al,
2005; Rivera et al, 2006). In Chapter 1, the strong correlation of p130Cas tyrosine
phosphorylation and FA localization was furthermore noted. Interestingly, previous
studies of cell migration in ∆SH3 mutants suggested a more modest reduction in cell
migration (Huang et al, 2002). These results were difficult to interpret, however, since
the protein was expressed at far lower levels than the full-length p130Cas variant and
was analyzed in a manner different from that used in this study. Specifically, Huang
et al (2002) calculated the area still left denuded after 24 hours of wound-healing
migration, whereas migration was analyzed as the translocation of individual nuclei
in the current study at time points no greater than 8 hours post-wounding.
Recently, a mechanosensing role for p130Cas in FAs has been proposed whereby
the physical extension of the SD makes it more accessible for phosphorylation by Src
(Sawada et al, 2006). The physical extension requires anchor points on both sides
of the SD, and it was proposed that anchoring is achieved by distinct interactions
made in FAs by the p130Cas SH3 domain and SBD. The proposed role for the SBD
in this mechanosensing model is based on the above-mentioned studies (Nakamoto
et al, 1997) that used a deletion mutant lacking the SBD but also part of the CCH
domain. The studies presented here now establish the CCH domain as the C-terminal
FA targeting region of p130Cas and thereby implicate the CCH domain, rather than
the SBD, as the C-terminal anchor point in the mechanosensing mechanism.
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CHAPTER III
THE DYNAMICS OF P130CAS LOCALIZATION IN FOCAL ADHESIONS
Introduction
It is known that tyrosine phosphorylation is important in regulating FA disassem-
bly, as inhibition of tyrosine phosphatases leads to the formation of large, stable FAs
(Inagaki et al, 2000). However, defects in FA disassembly are also seen when Src and
several Src substrates, such as p130Cas, are knocked down or mutated on tyrosine
residues (Webb et al, 2004).
Despite the role that p130Cas appears to have in regulating FA disassembly, noth-
ing is known about the dynamics of p130Cas localization and turnover in FAs. Most
studies of p130Cas localization and signaling have been performed by immunohisto-
chemistry experiments. Insights from live cell microscopy studies, therefore, could
enrich the understanding of how p130Cas regulates integrin-mediated signaling and
FA turnover. As live microscopy techniques have improved, much has been learned
about the structure of FAs and the dynamics of signaling in these structures. Such
advances have led to the understanding that the number of proteins in FAs, which
were previously thought to be in the range of 50, is actually likely to be more than 100
(Zaidel-Bar et al, 2003). Despite the fact that p130Cas is one of the most prominently
tyrosine phosphorylated proteins in FAs, it has been largely excluded from larger ad-
hesome studies (Zamir et al, 2000; Zaidel-Bar et al, 2003; Shroff et al, 2007; Zamir
et al, 2008; Winograd-Katz et al, 2009). In this chapter, I have incorporated data
about the residence of p130Cas in FAs, as well as data on the molecular exchange of
p130Cas in FAs that shed light on its transient tyrosine phosphorylation state.
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Materials and Methods
Cells and cell culture
Cas -/- MEFs were kindly provided by Hisamaru Hirai (University of Tokyo).
MEFs were grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with
10% fetal bovine serum (FBS) from Atlanta Biologicals (Lawrenceville, GA), 1% an-
tibiotic/antimicotic (Mediatech, Manassas, VA), 5 µg/ml plasmocin (InvivoGen, San
Diego, CA), and 1% non-essential amino acids (Invitrogen, Carlsbad, CA). TetFAK
cells were previously described in Owen et al (1999) and Chapter 2 “Materials and
Methods” and were maintained in the media mentioned above, which was furthermore
supplemented with 5 µg of tetracycline (Calbiochem, La Jolla, CA) per ml of media
to repress FAK expression. Phoenix Ecotropic (E) viral packaging cells (a gift from
Gary Nolan, Stanford University) were maintained in DMEM, supplemented with
10% heat-inactivated FBS, 1% antibiotic/antimicotic, and 1% non-essential amino
acids.
Plasmid construction and protein expression of p130Cas variants
Standard PCR-mediated mutagenesis strategies were used to create p130Cas-
Venus fusion proteins with Venus-YFP fused to the C-terminus of the p130Cas coding
sequence. For more details on the plasmid construction of LZRS-zeo-CasVenus(WT),
∆SH3, and ∆CCH, please see the “Materials and Methods” section in Chapter 2.
Plasmid mCherry-C1-paxilllin was generated to provide an FA marker for use in
live cell studies. The coding region of paxillin-α was subcloned into plasmid mCherry-
C1 (provided by Maria Nemethova, Vienna, Austria) from pGEX-2T-paxillin- α (pro-
vided by Hajime Yano, Osaka, Japan), such that paxillin is expressed with an N-
terminal mCherry tag (for more details on plasmid construction, see the “Materials
and Methods” section in Chapter 2). All plasmid sequences were confirmed before
use.
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Stable expression of p130CasVenus variants in Cas -/- MEFs was achieved by
retroviral infection using viral supernatants of Phoenix ecotropic (E) packaging cells
transfected with LZRS-zeo-Cas-Venus plasmids. Phoenix E cells were subjected by
calcium phosphate transfection in 60 mm culture dishes of cells plated at ∼60%
confluence. For a more complete description of the calcium phosphate transfection
technique and retroviral transduction, please see “Materials and Methods” in Chapter
2.
Three rounds of infection with viral supernatants were performed. For p130Cas-
Venus(∆SH3), it was necessary to select three clones of higher expressers to produce a
clonal population that expressed at levels equivalent to sorted cell populations (prior
attempts at achieving equivalent expression using cell sorting failed due to a rapid
loss of expression). All other p130CasVenus cell populations were further selected by
FACS to obtain a population in the lower half of the fluorescence ranges.
After infection and sorting for low levels of Venus-YFP, cells were periodically
maintained in media containing 10 µg/ml zeocin (Invitrogen) to assure continued ex-
pression from the bicistronic transcript that includes the bleomycin resistance gene
expressed from the internal ribosome entry site. Transient expression of mCherry-
paxillin was achieved by transfection with Lipofectamine LTX according to manufac-
turer’s instructions (Invitrogen) using 12 µl of reagent to 3 µg of DNA in OptiMEM
media (Invitrogen). Cells were incubated for 16 hours for transfection after which
cells were placed in normal DMEM supplemented as indicated above in “Cells and
Cell Culture”.
Quantification of pixel intensities at focal adhesions
Cas -/- MEFs expressing p130CasVenus variants transiently transfected with plas-
mid mCherry-C1-paxillin were grown to confluence on coverslips coated with 1 µg/ml
fibronectin. Two hours prior to analysis, scratch wounds were prepared by creating
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denuded areas using a pipette tip. Media was exchanged with complete media sup-
plemented with 10mM HEPES and cells were placed on the microscope stage in a
warming chamber maintained at 37◦C.
Cells migrating into the wound and expressing both fluorophores to appropriate
levels were chosen for analysis of dynamic FAs using TIRF microscopy, which was
performed on a Nikon ECLIPSE TE2000-E inverted microscope equipped with a
Perfect Focus System and a TIRF 100X/1.49 NA oil-immersion lens. Fluorophores
were excited with an 18 mW argon laser (Melles Griot, Albuquerque, NM) and 10
mW DPSS laser 85YCA010 (Melles Griot). A custom-made double-dichroic TIRF
mirror and emission filters (Chroma, Rockingham, VT) in a Ludl (Hawthorne, NY)
filter wheel were used to capture two-color movies.
Images were captured by a back-illuminated EM-CCD camera (Cascade 512B)
driven by IPLab software. Images were imported into ImageJ where file type was
converted to 8-bit grayscale. Background (non-cellular) was zeroed on each image by
adjusting the lower limit of the display range using the brightness/contrast function
in ImageJ.
Quantitative assessment of the dynamic localization of p130CasVenus and mCherry-
paxillin was made from plot profiles (obtained using ImageJ) of pixel intensities for
each fluorophore within a 3 pixel-wide line through the central longitudinal axes.
For p130CasVenus(WT), this analysis included 12 FAs from 4 different cells. These
images were captured every 25 seconds for 180 frames. The mean pixel intensities
were plotted as a function of time to find the time point at which fluorescence peaked
(this value was then used to delineate the end of assembly and the beginning of
disassembly). Apparent rate constants for FA assembly and disassembly were then
calculated from the slopes of semilogarithmic plots of the mean fluorescence intensi-
ties as a function of time (methodology adapted from Webb et al (2004)). To obtain
these semilogarithmic plots, the following equations for assembly or disassembly were
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plotted on the y axis and time was represented on the x axis:
Assembly = ln(|I|/|I0|)
Disassembly = ln(|I0|/|I|)
In these equations, ‘I0’ represents the initial fluorescence intensity of the FA, and ‘I’
represents the fluorescence intensity of the FA at a particular time point. Arrays were
constructed in Excel to determine the slope of a best fit line to these semilogarithmic
plots using the “least squares” regression approach. Statistical significance of mean
rate constants were determined using an unpaired, two-tailed, Student’s t-test.
For FRAP analysis in Cas -/- MEFs expressing p130CasVenus(WT), 20 FAs (each
from a different cell expressing p130CasVenus(WT) and mCherry-paxillin) were pho-
tobleached for 8 seconds with both 10 mW DPSS 85YCA010 and 30 mW argon lasers
(Melles Griot) by focusing the beam in the TIRF focal plane with a custom-made
lens (Nikon) placed in the position of the filter cube. In TetFAK cells, the number of
FAs was reduced to 7. Two-color movies were recorded every 2 seconds for 4 minutes
using TIRF microscopy as described above. FRAP curves and times of 50% recovery
were calculated and adjusted for chromophore activated laser inactivation effect ac-
cording to specifications previously described (Puthenveedu et al, 2006) using single
control measurements taken from each cell. Each channel in each FA was calculated
only in relationship to its own fluorescence recovery, with the value before bleaching
being set as the 100% mark from which the 50% recovery point was calculated.
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Results
P130CasVenus(WT) localizes to FAs throughout their lifetime
To further study dynamic aspects of p130Cas targeting to FAs, p130CasVenus(WT)
was visualized at the ventral interface of living cells using total internal reflection flu-
orescence (TIRF) microscopy. Dynamic adhesions in motile cells at the margins of
monolayer scratch wounds were analyzed. Fig. 22A shows images of a representative
FA recorded over a fifty minute time period.
Similarly to mCherry-paxillin, p130CasVenus(WT) localizes to FAs at the outset
of their assembly and persists throughout the process of disassembly. P130CasVenus
(WT) was consistently seen in a wide range of FAs from small FXs to larger, mature
FAs at the front and rear of the cell. The representative image in Fig. 22A shows an
FA where p130CasVenus(WT) happens to be more readily seen at the first stages of
FA assembly. However, in other instances paxillin could be more readily seen at these
earlier stages. Therefore, these data are not indicative of any differences in p130Cas
and paxillin arrival times in assembling FAs. The apparent extension of p130Cas
residence in FAs, however, was a consistent trait, which was furthermore quantitated.
As a further measure of p130CasVenus(WT) residence in FAs, assembly and dis-
assembly rate constants were determined by quantifying fluorescence pixel intensi-
ties over time, through the centers of the long axes of FAs. The bottom panels of
Fig. 22A show the resulting fluorescence intensity plots obtained for the representa-
tive FA shown. Such measurements obtained from 12 different FAs indicated that
the rate of p130CasVenus(WT) assembly into FAs was not significantly different from
that of mCherry-paxillin (Fig. 22B).
However, p130CasVenus(WT) appeared to disassemble from FAs at a slower rate
than mCherry-paxillin as was illustrated by calculating the apparent rate constant
of assembly and disassembly (Fig. 22B). These values were obtained as the slopes of
semilogarithmic plots wherein the initial fluorescence intensity of the FA was plotted
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Figure 22: P130CasVenus(WT) exists in FAs with similar dynamics to paxillin, but
disassembles in FAs at a slower rate. P130CasVenus(WT) cells transiently expressing
mCherry-paxillin were imaged by live TIRF microscopy at the leading edge of wound
margins to assess the dynamics of p130Cas localization to FAs relative to paxillin.
A. Images of a representative FA taken over a 49-minute time period. The graphs
show fluorescence intensity profiles obtained through the center of the long axis of
the FA (dotted line) at each time point. Scale bar is 5 µm. B. Mean assembly
and disassembly rates for p130CasVenus and mCherry-paxillin, calculated from the
fluorescence intensity profiles of 12 FAs from 4 different cells. Bars indicate the
standard error of the mean (SEM). Significance values were determined by Student’s
t-test where * indicates p = 0.22 and ** indicates p = 0.02.
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as a function of the FA fluorescence intensity over time (see “Materials and Meth-
ods” and Webb et al (2004) for a more detailed explanation of this function). Clearly,
p130Cas localizes to FAs throughout their lifetime.
P130Cas mutants display aberrant assembly and disassembly at FAs
P130CasVenus deletion mutants, ∆SH3 and ∆CCH, and CCHVenus display aber-
rant localization to FAs as compared to mCherry-paxillin. Attempts at determining
assembly and disassembly rates in these mutants were complicated by the indiscrete
manner with which they localize to FAs. Overall assembly of these proteins in FAs
does not correlate well with paxillin localization, which rises in a discernible peak.
Instead, the mutant fluorescence profile intensities in FAs display a number of ‘val-
leys and hills’ during assembly, which fall outside of the FA area itself (Fig. 23). The
∆SH3 mutant, in particular, displayed very static levels of protein localization over
time (Fig. 23, left panels), indicating that it was not able to appropriately assemble
into these sites and/or disassemble from them. The ability of the ∆CCH mutant to
assemble and disassemble in FAs varied widely, with some FA fluorescence profiles
roughly mimicking paxillin profiles (Fig. 23, middle panels) and other FAs exhibiting
a more static phenotype as was seen in the ∆SH3 mutant. CCHVenus fluorescence
profiles appeared dynamic, peaking in areas similar to paxillin, but also localizing,
assembling, and disassembling in areas adjacent to, but not within the FA (Fig. 23,
right panels).
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Figure 23: The dynamic localization of p130CasVenus mutants to FAs is non-discrete. P130CasVenus variants stably expressed
in Cas -/- MEFs were transiently transfected with mCherry-paxillin and imaged by live TIRF microscopy at the leading edge
of wound margins to assess the dynamics of p130Cas localization to FAs relative to paxillin. Images of representative FAs are
shown. The graphs show fluorescence intensity profiles obtained through the center of the long axes of FAs (dotted line) at each
time point. Scale bar is 5 µm.
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P130CasVenus(WT) exists in FAs with a high mobile fraction
To investigate the dynamic mobility of p130CasVenus(WT) in existing FAs, flu-
orescence recovery after photobleaching (FRAP) experiments were performed using
TIRF microscopy. In this manner, the recovery of fluorophores was only measured
within the ventral area of the cell where FAs exist. Again, mCherry-paxillin was used
as the point of reference. FAs were photobleached for 8 seconds and the subsequent
recovery of unbleached fluorophores was observed at 2-second intervals. The mean
time of 50% fluorescence recovery for p130CasVenus(WT) was ∼6 seconds, while 50%
recovery of mCherry-paxillin was significantly slower at ∼43 seconds (see Fig. 24).
The recovery curve for p130CasVenus(WT) plateaued at a higher level compared
to that of mCherry-paxillin. Thus, p130Cas exists dynamically in FAs with a high
mobile fraction.
Attempts at calculating recovery times for p130CasVenus mutants were again
complicated by their indiscrete localization. While recovery of fluorophore was de-
tected in the general area of the FA, it was clear from the recovery images that these
fluorophores did not incorporate into those areas in a significant manner as was seen
with p130CasVenus(WT) — data not shown.
Interestingly, by TIRF analysis the FA localization of p130CasVenus(WT) in Tet-
FAK non-induced cells is less adversely affected than is seen in p130CasVenus(∆SH3)
expressed in Cas -/- MEFs. Therefore, FRAP analysis of p130Cas defective in FAK
binding appeared more feasible by this methodology. When the rate of 50% recovery
was calculated, no significant differences in recovery were seen under the FAK-induced
conditions, but repressing FAK expression resulted in a more rapid fluorescence recov-
ery of p130CasVenus(WT). The increased recovery of p130CasVenus(WT) was also
concomitant with a larger mobile fraction (Fig. 25). The rate of paxillin recovery was
not significantly affected when FAK expression was repressed. However, the difference
in paxillin and p130Cas recovery was significant when FAK expression was repressed.
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Figure 24: p130Cas exists in FAs with a high mobile fraction. TIRF-FRAP was used
to study the exchange of p130CasVenus(WT) and mCherry-paxillin in individual FAs
at the leading edge of a wounded cell monolayer. After photobleaching, fluorescence
recovery was recorded at 2-second intervals. A. A representative FA is shown before
photobleaching (left panels), immediately after photobleaching (0”), and during fluo-
rescence recovery (10”-100”). Scale bar is 5 µm. B. Plot comparing the fluorescence
recoveries after photobleaching of p130CasVenus(WT) and mCherry-paxillin. Data
points represent the mean values of 20 individual FAs, with error bars indicating
SEM. The 50% mean fluorescence recovery time points are marked by arrows. Stu-
dent’s t-test showed the difference in 50% recovery points for p130Cas and paxillin
was significant at p < 0.001.
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Figure 25: In the absence of FAK expression, p130CasVenus(WT) exists as a higher
mobile fraction. Seven FAs from either TetFAK induced (A) or non-induced (B) cells
were photobleached for 8 seconds and the recovery of p130CasVenus and mCherry-
paxillin were monitored for 2 minutes in 2-second intervals. While there was no statis-
tical difference found between p130CasVenus(WT) and mCherry-paxillin in TetFAK
induced cells, in TetFAK non-induced cells this difference is significant at the level of
p < 0.001. Error bars represent SEM.
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Discussion
While it is recognized that p130Cas localizes to FAs where it engages in integrin-
mediated signaling via tyrosine phosphorylation (Petch et al, 1995; Fonseca et al,
2004; Ballestrem et al, 2006), the dynamics of p130Cas targeting to these sites remain
poorly understood. To investigate these issues, TIRF microscopy was used to visualize
fluorophore-tagged proteins in migrating fibroblasts.
Evaluation of p130Cas localization to FAs over time showed that p130Cas arrives
early during the assembly of FAs at the leading edge of motile cells, reaches peak
levels as FAs reach full maturity, and departs late during FA disassembly. These
observations are consistent with p130Cas having the capacity to function in FAs
throughout their lifetime. The rate of p130Cas assembly in FAs is similar to that
of paxillin, which is one of the first FA proteins detected in nascent FAs (Zaidel-Bar
et al, 2003). The early localization of p130Cas to assembling FAs supports the notion
that p130Cas engages in signaling at the leading edge of migrating cells to promote
plasma membrane protrusion. During FA disassembly, p130Cas actually appears to
persist longer than paxillin. This persistence is supportive of a proposed role for
p130Cas in promoting FA disassembly (Webb et al, 2004).
Note that the overall morphology of FAs (as marked by paxillin) appears normal
in cells expressing p130Cas mutants deficient in FA targeting, which is not surprising
as this is also true for Cas -/- MEFs (Honda et al, 1998). However, p130Cas has
been implicated in promoting FA disassembly (Webb et al, 2004) and SD tyrosine
phosphorylation in FAs could be involved in this process.
Though it is not possible to discern whether or not p130CasVenus(∆SH3) and
(∆CCH) contribute to the rate of p130Cas assembly and disassembly in FAs from the
anecdotal observations presented here, it is clear that these proteins are important
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for maintaining the spatial localization of p130Cas in the FA as it assembles and
disassembles. From the studies in Chapter 2, we can now deduce that the interaction
of p130Cas with FAs through the SH3 domain is mediated by FAK. Previous studies
have already shown that paxillin assembly and disassembly rates in FAs are reduced
14-fold in FAK -/- MEFs (Webb et al, 2004). However, in Cas -/- MEFs, this rate
is reduced an extra 5-fold. Therefore, it is likely that the CCH-binding partner
furthermore accounts for this reduced rate of paxillin disassembly. Finding the CCH-
binding partner, therefore, may create greater insight into the function of p130Cas
during disassembly.
Using FRAP, we found that p130Cas exchanges more rapidly with its binding
partner(s) in FAs as compared to paxillin. Thus the interactions made by p130Cas
in FAs appear to be relatively more transient and of lower affinity. Unlike pax-
illin, there is a large cytoplasmic reservoir of p130Cas that could be reflective of
the higher mobile fraction of p130Cas in FAs. As p130Cas SD phosphorylation is
linked to its localization in FAs (Fonseca et al, 2004), the high mobility of p130Cas
in FAs can account for the rapid turnover of SD tyrosine phosphorylation, as evi-
denced by sodium vanadate treatment. Though interpretation of the FRAP data on
p130CasVenus mutants was complicated by the inability of mutants to specifically
relocalize to these sites, performing FRAP experiments with TetFAK cells expressing
p130CasVenus(WT) demonstrated that the interaction of FAK with p130Cas may
in part regulate the mobility of p130Cas in FAs. Expression of FAK shifted more
p130Cas into the immobile fraction, whereas repression of FAK expression resulted in
a faster recovery of p130Cas to FA sites, which may be indicative of a faster release
of p130Cas from remaining binding partners. It is significant to note that the 50%
recovery rate for paxillin was faster (∼3-fold) in TetFAK cells in comparison to Cas
-/- MEFs. Perhaps the expression of Venus-tagged p130Cas in excess to endogenous
p130Cas can influence the rate of paxillin exchange in FAs (most likely through some
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indirect mechanism). Alternately, the level of FAK expression achieved in TetFAK
cells after 24 hours shifting into tetracycline-free media may differ significantly enough
from levels of FAK expression in Cas -/- MEFs to alter these rates.
While the interaction with p130Cas SH3 and CCH binding partners may influence
the molecular exchange of p130Cas in FAs, this rate may also be related to the degree
of p130Cas tyrosine phosphorylation in the SD. As previously discussed, FAK plays
a role in helping p130Cas achieve maximal SD tyrosine phosphorylation by acting
as a scaffold from which Src can phosphorylate p130Cas. Clearly, in TetFAK cells
wherein FAK expression is repressed, the tyrosine phosphorylation of p130Cas is
reduced (Fonseca et al, 2004). As we know that tyrosine phosphorylation of the
p130Cas SD is only detected in FAs (Fonseca et al, 2004; Ballestrem et al, 2006), it
is likely that the unphosphorylated species of p130Cas in the cytoplasm represents at
least part of the high mobile fraction of p130Cas.
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CHAPTER IV
PRELIMINARY STUDIES OF THE CCH DOMAIN STRUCTURE AND NOVEL
OBSERVATIONS OF P130CAS SUBCELLULAR LOCALIZATION
Introduction
In this chapter, I will discuss ongoing studies concerning the p130Cas CCH do-
main. As discussed in Chapter 2, a major direction of investigation that naturally
follows from the studies of the CCH domains influence on p130Cas FA targeting is to
obtain a better understanding of the protein structure. An attempt to investigate the
structure of the CCH domain indirectly by performing site-directed mutagenesis on
key amino acid residues in the putative four-helical structure will be discussed. Fig. 26
illustrates the putative tertiary structure of the CCH domain if it indeed adopts this
four-helical fold. Key residues for site-directed mutagenesis are also illustrated.
Figure 26: Putative tertiary structure of the CCH domain modeled against the FAK
FAT domain. The p130Cas CCH domain sequence was superimposed on the tertiary
structure of the FAK FAT domain to create a SWISS projection of its putative tertiary
structure with good stereochemisty. Residues postulated to be important for the
formation of the hydrophobic core (L823, L827, I830, L871)) are indicated.
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Lastly, the observed localization p130CasVenus in fibrillar adhesions, filopodia,
and cell-cell contacts will be discussed. These data represent preliminary and on-
going studies that have not been published, therefore few conclusions can be drawn
from them. They do, however, present good opportunities for future studies on the
targeting of p130Cas to its subcellular compartments. Such future studies will be
discussed at greater length in Chapter 5.
Materials and Methods
Cells and cell culture
Cas -/- MEFs were kindly provided by Hisamaru Hirai (University of Tokyo).
MEFs were grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with
10% fetal bovine serum (FBS) from Atlanta Biologicals (Lawrenceville, GA), 1% an-
tibiotic/antimicotic (Mediatech, Manassas, VA), 5 µg/ml plasmocin (InvivoGen, San
Diego, CA), and 1% non-essential amino acids (Invitrogen, Carlsbad, CA). TetFAK
cells were previously described in Owen et al (1999) and Chapter 2 “Materials and
Methods” and were maintained in the media mentioned above, which was furthermore
supplemented with 5 µg of tetracycline (Calbiochem, La Jolla, CA) per ml of media
to repress FAK expression. Phoenix Ecotropic (E) viral packaging cells (a gift from
Gary Nolan, Stanford University) were maintained in DMEM, supplemented with
10% heat-inactivated FBS, 1% antibiotic/antimicotic, and 1% non-essential amino
acids.
Antibodies
Monoclonal mouse antibodies to total p130Cas and paxillin were obtained from
BD Transduction Laboratories (San Jose, CA).
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Plasmid construction and protein expression of p130Cas variants
Standard PCR-mediated mutagenesis strategies were used to create p130Cas-
Venus fusion proteins with Venus-YFP fused to the C-terminus of the p130Cas coding
sequence. For more details on the plasmid construction of LZRS-zeo-CasVenus(WT)
and CCHVenus, please see the “Materials and Methods” section in Chapter 2. pCS2-
Cas L823E,L827E Venus was created by site-directed mutagenesis to change leucine
(Leu) residues 823 and 827 in the CCH to glutamic acid (Glu) residues. This pro-
cedure required three sequential steps of PCR amplification: 1) to amplify the mu-
tation from the 3’ end of the DNA template (pCS2-CasWT-Venus) using a pair of
oligonucleotide primers wherein the reverse primer contained the mutation and the
forward primer simply amplified the template sequence, 2) to amplify the mutation
from the 5’ end of the DNA template using another pair of oligonucleotides wherein
the forward primer contained the mutation, and 3) to extend the PCR products the
first two steps to obtain a complete PCR sequence. For the first step, the following
oligonucleotide primers were used: 5′- GCC ACC CAC ACT TCT GAC CGC ACC
-3′ (forward primer) and 5′- AC CTC GCC ACG CTC GAG GTC ACA CTC CA -3′
(reverse primer). For the second step, the oligonucleotides were: 5′-TG GAG TGT
GAC CTC GAG CGT GGC GAG GT-3′ (forward primer) and 5′-CCA TGA TTA
CGC CAA GCG CGC AAT TAA CCC TCA-3′ (reverse primer). The forward primer
from step 1 and the reverse primer from step 2 were then used to extend the PCR
sequences from steps 1 and 2 and furthermore amplify those sequences. Note that
these primers were designed to induce three Glu mutations, but resulted in only two
due to the difficulty of changing so many base pairs in close proximity to one another
using one set of primers.
PCR products were purified and cut by restriction enzymes BglII and Xba1, where
the BglII site is located in the p130Cas sequence lying at the 5′ end of the CCH domain
and Xba1 lies within the pCS2-Venus vector sequence. pCS2-Cas-Venus-WT was also
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cut using these sites and the PCR cut product was ligated in to the larger backbone
of this plasmid to replace the WT CCH sequence with the sequence containing the
Glu mutations. The DNA sequence was confirmed prior to transient transfection.
Stable expression of p130CasVenus variants in Cas -/- MEFs was achieved by
retroviral infection using viral supernatants of Phoenix ecotropic (E) packaging cells
transfected with LZRS-zeo-Cas-Venus plasmids. Phoenix E cells were subjected by
calcium phosphate transfection in 60 mm culture dishes of cells plated at ∼60%
confluence. For a more complete description of the calcium phosphate transfection
technique and retroviral transduction, please see “Materials and Methods” in Chapter
2.
Three rounds of infection with viral supernatants were performed. P130Cas-
Venus(WT) and CCHVenus cell populations were further selected by fluorescence
activated cell sorting (FACS) to obtain a population in the lower half of the fluores-
cence ranges.
After infection and sorting for low levels of Venus-YFP, cells were periodically
maintained in media containing 10 µg/ml zeocin (Invitrogen) to assure continued ex-
pression from the bicistronic transcript that includes the bleomycin resistance gene
expressed from the internal ribosome entry site.
TIRF imaging of p130CasVenus
Cas -/- MEFs expressing p130CasVenus variants were grown to confluence on
coverslips coated with 1 µg/ml fibronectin (from human plasma, Sigma-Aldrich, St.
Louis, MO). Two hours prior to analysis, scratch wounds were prepared by creating
denuded areas using a pipette tip. Media was aspirated from these cells to remove
cellular debris and fresh media was applied, which was furthermore supplemented with
10mM HEPES to maintain media pH when cells were placed outside of the incubator
on the microscope stage. Cells were imaged by total internal reflection fluorescence
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(TIRF) microscopy as previously described in Chapters 2 and 3. Fluorophores were
excited with an 18 mW argon laser (Melles Griot, Albuquerque, NM). A custom-made
GFP TIRF mirror and emission filters (Chroma Technology, Rockingham, VT) in a
Ludl filter wheel (Ludl, Hawthorne, NY) were used to capture frames at 25 second
intervals for a total of 180 frames.
Images were captured by a back-illuminated EM-CCD camera Cascade 512B
(Photometrics) driven by IPLab (Scanalytics, Fairfax, VA) software. Images were
imported into ImageJ (NIH – open source software), where file type was converted
to 8-bit grayscale. Background (non-cellular) was zeroed on each image by adjusting
the lower limit of the display range using the brightness/contrast function in ImageJ.
Imaging of filopodia by DIC and wide-field fluorescence microscopy
Scratch wounds were created, as described above, in confluent cell monolayers
on coverslips coated with 1 µg/ml fibronectin and analyzed by DIC and wide-field
fluorescence microscopy. The wounded monolayers were placed in complete DMEM
further supplemented with 10 mM HEPES, mounted into a 37◦C heating chamber
on an inverted Nikon ECLIPSE TE2000-E2 microscope, and visualized through a
100X/1.4 oil Plan Apo objective lens (Nikon). Wide-field fluorescence imaging was
achieved by placing a YFP filter in the excitation pathway. Frames were captured
every 25 seconds for 80 frames on a CoolSnapHQ camera (Photometrics) using IPLab
software.
Immunostaining CCHVenus cells for paxillin
Cas -/- MEFs expressing CCHVenus were fixed, immunostained for paxillin as an
FA marker, and visualized by wide-field fluorescence microscopy. Cells were grown on
coverslips coated with 10 µg/ml fibronectin (from human plasma, Sigma-Aldrich, St.
Louis, MO) and fixed for 5 minutes in 4% paraformaldehyde (in a buffer containing
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10mM MES, (pH 6.1), 138 mM KCl, 3mM MgCl2, 2mM EGTA, and 0.32M sucrose).
Paraformaldehyde was removed from slips by washing in a 50 µg/ml NaBH4 dissolved
in TBS and alternating with a TBS wash (washes were performed on ice). Cells were
then permeabilized for 10 minutes in 0.5% Triton-X in TBS. Slips were washed in TBS.
After blocking for 1 hour in a solution of 2% BSA and 0.1% Triton-X dissolved in TBS,
the coverslips were immunostained for paxillin with detection by Cy3-conjugated
secondary antibody. Coverslips were kept in the dark once secondary antibody was
added to prevent fluorophore degradation. The coverslips were mounted in Prolong
Gold Mounting Media (Invitrogen).
Images of immunostained cells were captured by QED Capture software (Media
Cybernetics, Silver Spring, MD) through a 100X/1.40 oil immersion lens on an upright
Nikon Eclipse 80i microscope (Nikon, Melville, NY) equipped with Nikon Epifluores-
cence D-FL attachments and a Photometrics Coolsnap ES camera (Tucson, AZ).
Fluorophores were excited by an EXFO X-Cite 120 fluorescence illumination sys-
tem (EXFO, Quebec, Canada) using Nikon C-FL G-23/C TRITC and C-FL B-2E/C
FITC filter cubes. After capture, TIFF images were imported into Adobe Photoshop
CS and the autocontrast function was used to adjust the images.
Results
Preliminary mutagenesis results
In Chapter 2, we showed that the CCH domain of p130Cas has a significant role in
localizing p130Cas to FAs. As previously noted, the structure of the CCH domain has
not been solved, yet there are at least two theories on what the secondary structure of
the CCH may be: 1) the CCH may contain four α-helices, similarly to the FAK FAT
domain (Arold et al, 2002; Hayashi et al, 2002; Liu et al, 2002; Garron et al, 2009),
or 2) it may contain three α-helices and an area of β-strand content in the area that
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would be analogous to the second helix in the FAK FAT domain (Singh et al, 2008).
Therefore, the possibility that the CCH domain may contain alpha helices that
bundle similarly to the FAK FAT domain in the third and fourth areas predicted to be
helices seemed plausible. Residues that may play an important role in maintaining the
hydrophobic interactions between the third and fourth helix were therefore identified
for site-directed mutagenesis. In the FAK FAT structure, two leucine (Leu) and a
valine (Val) residue are indicated in the third helical area, as well as a Val and Leu
residue in the fourth helical area. All of these sites are also well conserved in p130Cas
and its family members, though the Leu residue in the fourth helix is an isoleucine
(Ile) in DmCas (which is nevertheless a hydrophobic residue). Therefore, mutation of
some of these analogous residues in p130Cas was used to investigate the importance
of hydrophobic residues in the ability of the CCH domain to target to FAs. It stands
to reason that if the CCH targeting mechanism is interrupted by one or several of
these mutations, that the CCH domain may contain similar structural features to
the FAK FAT domain (i.e. loss of targeting by the CCH would be correlated with a
disruption of CCH domain tertiary structure).
Mutants were generated based on the existing DNA plasmid, pCS2-Cas(WT)-
Venus. Mutagenesis of two Leu residues (823 and 827) implicated in helix bundling
to Glu residues (effectively making these hydrophobic residues acidic) was evalu-
ated by transiently transfecting Cas -/- MEFs with the DNA plasmid pCS2-Cas-
L823E,L827E-Venus and imaging cells by TIRF microscopy (Fig. 27).
Localization of this p130CasVenus(L823E,L827E) was variable, though most cells
appeared to lack normal FA localization. As seen in Fig. 27, some cells did present
some areas of dense localization at the periphery (right image), though it is not clear
from this experiment whether or not these sites are FAs. Further complicating the
determination of whether or not these cells display localization of CasVenus to FAs is
the fact that the cells did not appear well-spread. Further study, is therefore necessary.
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Figure 27: The FA localization of p130CasVenus(L823E,L827E) appears defective.
TIRF imaging of Cas -/- MEFs transiently expressing Cas-L823E,L8237E-Venus
through a 100X objective lens. Two representative images of transfected cells are
shown. Scale bar is 10 µm.
The localization of p130Cas in fibrillar FAs is influenced by the CCH domain
In Chapters 2 and 3, the localization of p130Cas to leading edge FAs and FXs
was discussed. However, there are other classes of ECM/cell contacts in the cell,
including the trailing edge FAs and the fibrillar adhesions. Using TetFAK cells,
it became apparent that the localization of p130CasVenus variants in leading edge
FAs differed from the localization in fibrillar adhesions. When FAK was expressed,
p130CasVenus(WT) could be detected at fibrillar adhesions. Surprisingly, the amount
of p130CasVenus(WT) fluorescence increased in fibrillar adhesions when FAK was not
expressed. The ∆CCH mutants did experience some significant loss of targeting at
fibrillar adhesions, which was furthermore reduced in the absence of FAK expression.
However, complete loss of targeting was never seen (Fig. 28).
Localization of p130CasVenus to filopodial tips
By TIRF, small speckles of p130CasVenus(WT) were occasionally seen beyond
the edge of where the lamellipodium appeared to be, in a manner that did not appear
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Figure 28: P130CasVenus localizes to fibrillar adhesions in a CCH-dependent, but
FAK-independent manner. Quantitative analysis of meanp130CasVenus fluorescence
at fibrillar adhesions. Paxillin immunofluorescence was used to delineate FA bor-
ders in confocal images of TetFAK cells expression p130CasVenus (see Chapter 2 for
images), and mean Venus-YFP fluorescence values were measured from within the
FA boundary. For each p130Cas variant, mean Venus-YFP fluorescence was deter-
mined from 50 FAs (10 each from 5 separate cells). Bars indicate SEM. Statistical
significance was determined by Student’s t-test.
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Figure 29: Small speckles of p130CasVenus are seen beyond the general leading edge
of cells by TIRF, which do not appear to be FA structures. Cas -/- MEFs expressing
p130CasVenus(WT) were imaged at the edge of a wounded cell monolayer by TIRF
microscopy. Arrows indicate the position of speckles. The time stamp is indicated on
each image corresponding to the time in minutes:seconds. Scale bar is 5 µm.
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Figure 30: P130CasVenus localizes to the tips of filopodia. Cas -/- MEFs expressing
p130CasVenus(WT) were imaged at the edge of a wounded cell monolayer by DIC and
wide-field fluorescence microscopy. Arrows indicate the tip of the filopodium. The
time stamp is indicated on each image corresponding to the time in minutes:seconds.
Scale bar 5 µm.
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consistent with FA or FX localization (Fig. 29). These speckles moved rapidly
in various directions without showing obvious turnover. Since it was not possible
to discern the outline of the cell by TIRF imaging (hence making it impossible to
discern what structures these speckles occurred in), DIC imaging and wide-field fluo-
rescence microscopy were used to discern where these speckles were occurring. Using
this technique, the small speckles were found to localize at the distal tips of filopodia
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(Fig. 30). Imaging of these structures over time showed that the speckle remained
localized to the tip and did not track along the length of the filopodium. These data
constitute the first observation of p130Cas at filopodial tips in live cells. p130Cas has
been observed in areas that appear to be filopodia by immunostaining (Gustavsson
et al, 2004).
CCHVenus can localize to areas of cell-cell contact
Previously, p130CasVenus(WT) was found to localize to cell-cell contacts of Caco-
2 cells that were well-polarized (Lund, 2008), whereas HCF-7 cells, which are not as
well polarized did not display such a localization. The mechanism by which p130Cas
localized to these sites was not further investigated. By immunostaining, p130Cas
had also been found to localize to cell-cell junctions in kidney epithelial cells.
It is therefore interesting to note that in fibroblasts that exhibited close contact
with one another, CCHVenus could sometimes be seen in sites that appear to be
nascent cell-cell contacts (Fig. 31). When cells were fixed and stained for paxillin,
CCHVenus could be seen aligning along the periphery of cells where they made con-
tact with one another, yet paxillin, which remained localized to FAs, was not seen in
those sites. The localization of p130Cas at these sites appeared in a perpendicular
angle to the cell-cell contacts themselves, in a pattern similar to stitches.
Discussion
Though the data presented for the p130CasVenus(L823E,L827E) mutant are by no
means conclusive, this technique shows promise for the elucidation of specific residues
important for the localization of p130Cas to FAs through the CCH domain. Future
experiments will require that the cells be allowed to spread for longer amounts of
time and that cells be cotransfected with an FA marker, such as mCherry-paxillin.
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Figure 31: CCHVenus can localize to cell-cell contact areas. Cas -/- MEFs stably
expressing CCHVenus were fixed in 4% paraformaldehyde and labeled for FAs with
paxillin immunostaining. A representative cell that was imaged by wide-field fluores-
cence microscopy is shown along with enlarged insets of each channel. CCHVenus is
shown in green and paxillin immunostaining in red. Cells were imaged with a 100X
lens. Scale bar is 10 µm.
Additionally, studying this mutant in the context of the CCHVenus instead of the full-
length protein should present a more definite idea of what these residues contributions
to localization are. If this mutant is found to be defective in FA localization after
further study, it would also serve as a useful tool for the identification of possible
CCH binding partners (where this mutant could serve as a negative control in CoIP
experiments.
As fibrillar adhesions are known to develop and mature for leading edge FAs
(Zamir et al, 1999; Volberg et al, 2001), a loss of CasVenus fluorescence under FAK
repressed conditions seems logical (since this might prevent the accumulation of other
FA components in fibrillar adhesions). However, this does not appear to be the case,
since CasVenus accumulates at a higher level in fibrillar adhesions when FAK is
absent. Data obtained from TetFAK cells are suggestive of a particular role for the
CCH domain in fibrillar adhesions and furthermore suggest that in the absence of the
CCH domain, p130Cas may interact with other binding proteins either through its
SH3 domain or other domains to localize p130Cas to these sites. To further explore
the possibility of p130Cas switching SH3 domain partners at fibrillar adhesions, it
would have been interesting to investigate the ∆SH3/∆CCH domain mutant in this
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context.
Since FAK does not appear to be a key fibrillar adhesion component (Zamir and
Geiger, 2001) and its expression negatively affected CasVenus localization to fibrillar
adhesions, a role for FAK in localizing p130Cas to fibrillar adhesions seems unlikely.
As previously discussed, loss of the association between p130Cas and FAK leads
to reduced SD tyrosine phosphorylation due to a loss of Src-binding to the FAK
autophosphorylation site (Ruest et al, 2001). Though fibrillar adhesions have a rel-
atively lower pTyr content than FAs (Katz et al, 2000), it is possible that p130Cas
SD tyrosine phosphorylation is a key process in its incorporation to these sites. As
discussed in Chapter 1, a distinctive feature of fibrillar adhesions is their tensin con-
tent. Interestingly, when CHO cells are stimulated by GH, p130Cas/CrkII complexes
form that also contain tensin (Zhu et al, 1998). As GH stimulation leads to increased
tyrosine phosphorylation p130Cas, it would be interesting to determine whether or
not the loss of p130CasVenus(∆CCH) in fibrillar adhesions was due to a reduction in
tyrosine phosphorylation at these sites. Staining cells that exhibit fibrillar adhesions
for Crk, may create some insight as to whether or not p130Cas SD phosphorylation
and specifically, p130Cas/Crk coupling is involved in this localization. Mechanotrans-
duction through p130Cas may also play a critical role, which might account for the
reduction in targeting to fibrillar adhesions when the CCH domain is absent. In order
for fibrillar adhesions to form, tensile forces on mature FAs must pull on these sites,
resulting in the translocation of tensin and integrins to fibrils (Pankov et al, 2000).
If mechanotransduction by p130Cas is aberrant in leading edge FAs, it may further-
more disrupt fibrillar adhesion formation. Considering the importance of p130Cas to
mechanotransduction in FAs, an overall analysis of fibrillar adhesion number and size
may also be warranted.
While it is difficult to come to any conclusions about the role of the p130Cas CCH
in the formation of cell-cell contacts from these studies, the observation that such a
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localization can occur sets a foundation for further investigation. Since fibroblasts
do not form true cell-cell junctions, it would be useful to study the localization of
CCHVenus is an epithelial cell line which is able to efficiently polarize in an apical-
basolateral fashion. In kidney epithelial cells, p130Cas has been seen at cell-cell
junctions with ZO-1 and Nephrocystin (Donaldson et al, 2000). The interaction be-
tween p130Cas and Nephrocystin was abrogated when the Nephrocystin SH3 domain
was deleted. Therefore, it appears that the p130Cas SBD may recruit Nephrocystin
to these sites. Since expression of Nephrocystin appears primarily in adult kidney
tissues, it seems unlikely that the localization of p130CasVenus(WT) to cell-cell con-
tacts of Caco-2 cells (intestinal epithelial cell line) would be mediated by the same
interaction.
The expansion of cell-cell contacts and their maturation into cell-cell junctions is
a carefully coordinated process that requires both lamellipodial protrusion driven by
Rac1 and Arp2/3 as well as contractile forces exerted by RhoA and myosins (Yamada
and Nelson, 2007). It is therefore possible that p130Cas is initially recruited to sites
of cell-cell contact to promote actin polymerization. Alternately, p130Cas may be
involved at these sites to promote an epithelial to mesynchemal transition (EMT),
whereby well-polarized cells adopt a more promotile phenotype. Indeed, siRNA tar-
geting of p130Cas in Caco-2 cells results in greater polarization than scamble siRNA
as measured by a transwell resistance assay (Lund, 2008). While this localization to
cell-cell contacts was observed with CCHVenus, the same observation was not made
with p130CasVenus(WT) cells, suggesting that the use of this single domain may have
stabilized what may otherwise be a more transient interaction. Identification of CCH
binding partners, therefore, could be useful to perform overexpression experiments to
attempt to stabilize the localization of the full-length p130Cas to these sites.
The observation of p130CasVenus(WT) to the distal tips of filopodia may also
be related to cell-cell contact localization. Filopodia form in a response to migratory
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stimuli, cell spreading, and formation of cell-cell contacts (Partridge and Marcantonio,
2006; Mattila and Lappalainen, 2008). In epithelial cells, filopodia are implicated in
“zippering” epithelial cells together (Mattila and Lappalainen, 2008), a pattern that
looks somewhat reminiscent of the “stitch” appearance seen in CCHVenus cell-cell
contacts. Formation of these zippering sites is correlated with actomyosin contrac-
tion, which is important in establishing apical-basolateral polarization. Alternatively,
p130Cas may be localizing to these filopodial tips to promote new FA formation
and/or actin polymerization. During cell spreading, filopodia extend and generate
de novo FAs. These filopodia are integrin-rich and recruit other FA proteins in a
sequential manner as FAs form at their tips (Partridge and Marcantonio, 2006). One
might therefore imagine a scenario, where p130Cas, which is closely linked to integrin
signaling, can promote actin polymerization at tips of filopodia and may function
to recruit and/or assemble FA proteins at these sites. In response to invasin (β-1
integrin ligand from Yersinia tuberculosis), p130Cas has been observed in areas of
high pTyr staining that appear to be filopodia tips (Gustavsson et al, 2004). The
authors also showed the CrkII localizes to these tips and that filopodial extension is
defective when the SD is deleted (Gustavsson et al, 2004). Interestingly, Rac appears
to be necessary for filopodial extension in response to invasin ligation, but not Cdc42
(Gustavsson et al, 2004). p130CasVenus variants could therefore serve as a useful
tool for dissecting the manner of p130Cas targeting to filopodial tips.
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CHAPTER V
CONCLUDING REMARKS AND FUTURE DIRECTIONS
Concluding Remarks
The observation that p130Cas is elevated in tamoxifen-resistant breast cancer pa-
tients (van der Flier et al, 2000; Brinkman et al, 2000) and that it can also cause drug
resistance to other drugs such as adriamycin (Ta et al, 2008), makes p130Cas a protein
of interest for the development of cancer treatments. It is clear that p130Cas SD sig-
naling is involved the ability of p130Cas to promote tumorigenesis (Soni et al, 2009;
Cunningham-Edmondson and Hanks, 2009). Therefore, understanding the mech-
anisms by which p130Cas promotes such signaling is central to developing better
therapies. The importance of p130Cas in integrin signaling and actin reorganization
has long been noted (Petch et al, 1995; Nojima et al, 1995; Honda et al, 1999). Pre-
vious studies have shown that p130Cas SD signaling occurs at FAs (Fonseca et al,
2004; Ballestrem et al, 2006), yet the mechanisms by which this localization occurs
was left unclear due to conflicting reports by Nakamoto et al (1997) and Harte et al
(2000). The data presented in this thesis clarify the mechanism of p130Cas targeting
to FAs by illustrating that the SH3 interaction with FAK plays an important role in
localizing p130Cas to FAs, in addition to identifying the CCH domain as a separate
site of FA targeting.
The importance of p130Cas FA localization was furthermore emphasized by show-
ing that disruption of the p130Cas FA targeting mechanism leads to defective SD
signaling and p130Cas-enhanced cell motility. It is clear from previous studies that
SD signaling and p130Cas coupling of SH2 adapter proteins are key events during
p130Cas signaling to promote cell motility (Klemke et al, 1998; Schlaepfer et al,
1997; Huang et al, 2002; Shin et al, 2004). Actin polymerization as a result of this
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SD signaling does not appear to be the only mechanism by which p130Cas promotes
cell motility, however, as evidenced by the observation that Cas -/- MEFs exhibit FA
disassembly defects (Webb et al, 2004). Aberrant FA formation and reduced disas-
sembly of FAs has been linked to cell motility defects in FAK -/- cells as well (Ilic
et al, 1995; Webb et al, 2004).
Therefore, the data presented in Chapter 3 demonstrating that p130Cas resides in
FAs throughout their lifetimes and disassembles at a slower rate in FAs than paxillin
creates insights into the mechanisms of p130Cas regulation of overall FA disassembly.
Clearly, the persistence of p130Cas in FAs at later time points of disassembly are
consistent with a role for this docking protein in regulating the disassembly of other
FA proteins from these sites (which was demonstrated previously by Webb et al (2004)
by analyzing the turnover of paxillin in Cas -/- MEFs). Additionally, the observation
that p130Cas has a high mobile fraction suggests that p130Cas exchanges in FAs
in a dynamic manner, which may be critical to its role in FA signaling. These data
provide an explanation for the transient tyrosine phosphorylation of p130Cas that was
previously noted by Fonseca et al (2004). In light of observations made by Brown
et al (2006) and Hu et al (2007) that FA components that bind F-actin exhibit faster
dynamics than those located closer to the integrin interface, one may speculate that
p130Cas might associate with an FA protein linked to F-actin. On the other hand,
p130Cas clearly associates with FAK in FAs, and the retrograde flow of FAK in FAs,
while it is coherent with actin retrograde flow, is still slower than the actin flow (Hu
et al, 2007). If p130Cas were linked into FAs by one domain at a closer proximity to
integrins (perhaps the SH3 domain) and to an actin-bound FA protein by the other
domain (maybe the CCH domain), then p130Cas would be poised to act a sort of lever
in FAs, whereby actomyosin contractility might be modulated. Such an association
would be consistent with the mechanotransduction model of p130Cas SD signaling
proposed by Sawada et al (2006). As FAs mature and greater force is applied to these
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sites from stress fibers linked to FAs, p130Cas would become increasingly stretched,
exposing its SD residues.
Observations of p130Cas localization to other subcellular compartments such as
fibrillar adhesions, filopodial tips, and areas of cell-cell contact further emphasize that
this is a protein that is closely linked to a variety of integrin- and actin-associated
structures. It is likely that p130Cas can be recycled into a variety of these structures
through its association with integrins and actin. For example, it is not difficult to
conceive that integrins that were initially bound in FAs could be redistributed into
filopodia and that p130Cas may be in complex with these integrins (directly or indi-
rectly).
Future Directions
Identifying CCH binding partners
Though the studies presented here show that the CCH domain is an important FA
targeting domain, the molecular mechanism by which this domain localizes p130Cas
to FAs remains unknown. Identifying proteins which bind the p130Cas CCH do-
main would therefore be a logical step forward. Using CCHVenus cells to perform
CoIP experiments, for instance, might be a good way to identify interacting partners.
GFP antibodies that have the ability to IP YFP are commercially available. Alter-
natively, CoIP experiments with full-length p130Cas and the CCH deletion mutant
could be used to identify binding partners that are lost in the latter case. Use of
the p130Cas(WT) and p130Cas(∆CCH) may offer the advantage of capturing inter-
actions that may first require the assembly of p130Cas complexes through its other
interaction domains. As construction of p130Cas mutants with individual residues
mutated in the CCH domain are currently in development, these mutants could also
be used in CoIP experiments.
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One consideration that may complicate CoIP experiments is the fact that the
interaction of p130Cas with FAs appears to be so transient. Therefore, it may be
necessary to perform reversible cross-linking of proteins in cell lysates in order to
detect these interactions. Once IP experiments are performed, the products can be
run separated by SDS-PAGE, visualized by Coomassie staining, and bands of interest
can be isolated for identification by LC/MS/MS (liquid chromatography and two runs
of mass spectrometry).
Though IP of proteins that were processed intracellularly is preferable, binding
proteins may also be identified by using a His-tagged construct of the CCH domain
to perform a pull-down assay. In this scenario, the recombinant protein bound to
Nickel beads would be incubated with whole cell lysates from fibroblasts in hopes of
capturing interacting proteins. This assay may be complicated, however, by the fact
that this recombinant protein is difficult to elute off the bead (data not shown). Use
of thrombin cleavage to remove the CCH domain from the His-tag and therefore the
bead, has also been unsuccessful. The CCH domain remains bound to the bead, pre-
sumably because of some other interaction that may be a result the domains tertiary
folding.
Probing the CCH domain structure
An ongoing collaboration with the lab of Jie Zheng, Ph.D. at St. Jude Children’s
Hospital in Memphis, TN has led to a new prediction for the tertiary structure of the
CCH domain. The Zheng lab used a longer His-tagged construct that also includes the
SBD (including the YDYV motif thought to bind the Src SH2 domain) and suggest
that the area including the SBD could form a fourth α-helix (by secondary structure
prediction). Should NMR structure data corroborate these predictions, the extended
domain would be a somewhat novel FA targeting structure with some similarities to
the FAK FAT domain. Interestingly, the FAK FAT domain contains a YENV motif at
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Tyr925 in the first α-helix whose accessibility to phosphorylation has been postulated
to be unlikely without structural remodeling (Arold et al, 2002). Simulations of FAK
FAT domain “unraveling” have been performed, with an estimation that mechan-
otransduction forces could unfold the four helical bundle of the FAK FAT domain
and lead to a dissociation of FAK and paxillin (Mofrad et al, 2004). However, the
effect on Tyr925 exposure was not specifically included in this analysis.
Until an NMR structure of the CCH domain is obtained, continued studies by
site-directed mutagenesis of this domain may be useful to identify features important
for its localization to FAs. In addition to the amino acids mutated in Chapter 4 (L823
and L827), other residues may play a role in the helical bundling of the CCH domain
(if these helical bundles in fact exist): I830 and L871. A single CCH mutant plasmid
(in the context of the full-length protein) has been generated for L827, but has not
yet been evaluated. It will most likely be preferable to evaluate the localization of
this mutant in the context of CCHVenus by itself. Additionally, the surface patch
that has been implicated in the binding of paxillin LD motifs by the FAK FAT is
formed between helices 2 and 3 of the FAK FAT domain. By mutating the follow-
ing residues on the CCH domain, a better idea of whether or not a surface patch is
involved in recruiting the CCH domain to FAs could be evaluated: Lys787, Asp801,
and Lys835. Development of the Lys787 mutant (mutated to Ala) in the context of
the CCH domain is currently under way. Since these mutants are being created on
the basis of similarity to the FAK FAT domain, it may be interesting to compare
their localization of a comparable WT FAK FAT fusion protein. Subcloning of such
a DNA construct is currently under way. However, it may be difficult to evaluate
differences of localization between the FAK FAT and CCH domains in the context of
the same cell, as the FAK FAT domain essentially functions as a dominant negative
(which may cause the mislocalization of the CCH binding partner if it is reliant on
the localization of FAK to FAs). Since p130CasVenus still localized to FAs in the
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absence of FAK expression, it may however, be reasonable to expect that the CCH
domain could still localize to FAs.
Elucidating features of the p130Cas mobility in FAs
Using FRAP to analyze the recovery of p130CasVenus in comparison to actin and
integrins might offer greater insight into the transience of p130Cas at FAs. In partic-
ular, it would be interesting to perform FRAP in nascent FXs in comparison to FAs
and observe whether or not the stage of FA maturation can affect the transience of
p130Cas localization. Though the SH3 and CCH mutants do show reduced phospho-
rylation, it may be necessary for p130Cas to be completely dephosphorylated in order
to dissociate from FAs. Therefore, use of phosphatase inhibitors during FRAP may
be an interesting tool. If the mobile fraction reflects a pool of p130Cas that is not
phosphorylated on tyrosine, application of a phosphatase inhibitor should lead to a
smaller mobile fraction. Alternately, if tyrosine phosphorylation serves as cue for the
dissociation of p130Cas from FAs, the expression of an SD mutant might increase the
immobile fraction and retard the recovery of fluorophores to FAs after photobleaching.
Investigating the localization of p130Cas in other subcellular compartments
Though the current studies have created a clearer understanding of what domains
in p130Cas are required for its localization to leading edge FAs (and partially to
fibrillar adhesions), a more complete study of domains required for the localization
of p130Cas to other classes of ECM/cell contacts is still lacking. For instance, it is
still not clear which domains are required for the localization of p130Cas to FXs and
podosomes (actin-rich invasive structures at the ECM/cell interface). Cells developed
for the studies in this thesis, which express p130CasVenus variants, would therefore
be useful tools in such future studies. To understand what domains are required for
focal complex localization, for instance, cells can be stimulated to form FXs by the
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application of a ROCK inhibitor or by driving Rac activity by transfecting cells with
a constitutively active Rac construct (Zaidel-Bar et al, 2003). Paxilllin and/or talin
could be used as markers of FXs in such a setting and the localization of p130CasVenus
variants can be similarly studied as was done in Chapter 2 in leading edge FAs.
To study the localization of p130CasVenus variants in podosomes, the cells used
in the current study could be stimulated with phorbol esters or transfected with a
constitutively active Src DNA construct to promote podosome formation. Immunos-
taining cells for tyrosine phosphorylated cortactin would serve as a good marker for
podosomes. Colocalization of p130CasVenus constructs with cortactin in such cells
could then be used to evaluate the contribution of these domains to p130Cas localiza-
tion in podosomes. Previous studies in Cas -/- MEFs have shown that the formation
of podosomes is greatly reduced in comparison to Cas +/+ MEFs when they are
transformed with a constitutively active Src (Brabek et al, 2004). Formation of large
podosome structures was also inhibited when p130Cas variants with SD and SBD
mutations were expressed in Cas -/- MEFs (Brabek et al, 2005). However, expression
of an SH3 mutant did not significantly reduce the numbers of large podosomes formed
in response to Src-transformation. Yet, the activation of matrix metalloproteinase-2
was reduced in cells expressing the SH3 mutant. Using phospho-specific antibodies to
the p130Cas SD, Alexander et al (2008), demonstrated that p130Cas is localized and
phosphorylated in invadopodia. Since invadopodia/podosomes are ECM/cell contacts
composed of many of the same components present in FAs, it is likely that some of
the same mechanisms that regulate p130Cas localization to FAs may be necessary for
the localization of p130Cas to podosomes.
The observation of p130CasVenus at the tips of filopodia is intriguing. dDia2
has been found at filopodial tips and is thought to act as a an inhibitor of actin
filament capping, thereby promoting continued filopodial protrusion. Src is known
to interact with dDia2. It would be interesting to know if p130Cas functions in
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this compartment to promote 1) actin polymerization or 2) a Src/dDia2 interaction.
Interestingly, myosin X has also been found at the tips of filopodia, where it has been
implicated in the trafficking of integrins (Zhang et al, 2004), presumably to test out
the ECM for sites of ligation. It would be interesting to further elucidate the function
of p130Cas in filopodia. Using transient expression of a constitutively active form of
Rho in filopodia (Rif) to produce filopodial extension leads to the formation of so
many filopodia that the cells appears “hairy” (Ellis and Mellor, 2000). This approach
would be a great tool do determine whether or not p130CasVenus variants, such as
the ∆CCH are capable of localizing to filopodia or not. Additionally, this approach
would allow useful to perform colocalization experiments in which the colocalization
of p130Cas with formins or myosins in filopodial tips (either by immunostaining or
cotransfection) could be monitored.
The localization of p130Cas in filopodia could also be related to its localization in
cell-cell junctions (as observed in epithelial cells by Lund (2008)). One of the func-
tions of filopodia is to sense where other cells are and make contact with them. In-
deed, in endothelial cells, myosin-X and vascular endothelium-cadherin (VE-cadherin)
colocalize at filopodial tips (Almagro et al, 2010), where the FERM domain binds
VE-cadherin and transports VE-cadherin to the filopodial tips. Interestingly, in a
yeast two-hybrid screen for proteins that interacted with the C-terminus of p130Cas
(including the SBD), myosin-X was implicated as an interacting partner (unpublished
data from the screen conducted by Donaldson et al (2000).) This interaction was not
demonstrated in mammalian cells, however.
Clearly, the studies performed for this dissertation have elucidated many aspects
of p130Cas FA localization. With the new insights created by these studies, new ques-
tions and observations have arisen that may be promising avenues of future study.
Continued efforts to understand domain contributions to p130Cas subcellular localiza-
tion are well-warranted, as this protein’s localization is so heavily implicated in cell
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signaling pathways affecting various cell functions such as cell migration, invasion,
survival, and pathogenesis.
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